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Chapter 1  
 
Introduction and outline of this thesis 
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1.1 Down syndrome 
Down syndrome, which is synonymous with trisomy 21 (47, +21), is the most common 
chromosomal anomaly in live born children. In 1866 John Langdon Down first described 
children with common phenotypically features distinct from other children with mental 
retardation 1. These children were referred by Down as ‘mongoloids’, based on the typical 
facial characteristics of individuals with Down syndrome. Specific characteristics of newborns 
with Down syndrome include  a flat nasal bridge, epicanthic folds, small ears, a protruding 
tongue, a short neck and hypotonia 2. Beside the visual features, newborns with Down 
syndrome have an increased risk of congenital structural anomalies such as heart defects, 
gastrointestinal defects, hearing and ophthalmic problems, hypothyroidism and leukemia 3-7. 
In 1956 Joe Hin Tjio and Albert Levan 8 reported that  the total number  of human 
chromosomes in ‘normal subject’ is 46, rather than 48 as was supposedly established some 
three decades earlier. The importance of this finding was not the total number of 
chromosomes itself, but rather the ability to distinguish the number of 46 chromosomes from 
numerical chromosomal abnormalities. In fact, it was three years later (1959) when Lejeune 
et al 9 demonstrated that Down syndrome is associated with  the presence of an additional 
chromosome 21. Due to this extra copy of chromosome 21, the clinical condition Down 
syndrome is also known as trisomy 21. As a result of the technical advances in chromosomal 
analysis of  human amniotic-fluid cells demonstrated by Steele and Breg 10, the first prenatal 
diagnosis of Down syndrome by amniocentesis was reported in 1968 11. Because  of the 
development of the new obstetric techniques together with the advances in direct analysis of 
spontaneous mitoses in fetal tissue 12 it was possible from 1989  to carry out prenatal 
chromosome diagnosis in  the first trimester of pregnancy. Chorionic villi, which typically 
have the same genotype as the fetus, were obtained by gentle suction under constant real-
time ultrasound guidance. These techniques enabled pregnant women to choose between 
chorionic villus sampling (CVS) at the 9th to 11th week of gestation and amniocentesis at the 
16th to 18th week of gestation. These invasive procedures are associated with an iatrogenic 
miscarriage rate of 0.3- 0.5% 13-18. 
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For The Netherlands nowadays the estimated birth prevalence of Down syndrome is 14 per 
10.000 with around 322 total annual births 19,20. The relatively high prevalence of this 
condition and the association with perinatal morbidity and mortality has been one of the main 
reasons for the implementation of prenatal screening for Down syndrome.  
 
1.2 Screening 
The outline for a successful screening programme for any disease was formulated by Wilson 
and Jungner in 1968 21. They argued that the concept of screening is different from 
diagnosis. Screening tests help to identify a specified disease or condition among 
asymptomatic individuals while diagnostic tests are carried out among individuals with signs 
or symptoms of the condition of interest 22. They claimed that a successful screening 
programme should need the following requirements (Table 1). 
 
Table 1 Desirable characteristics for a successful screening programme 
1. Is the condition being screened for an important health problem? 
2. Is the screening test and its consequences in terms of further diagnostic testing and 
subsequent treatment acceptable to the population? 
3. Does the target condition have a recognizable latent and early symptomatic phase? 
4. How valid and reliable is the screening test? 
5. Are there adequate facilities for confirming the diagnosis and for adequate 
treatment? 
6. Is the screening programme a continuing process and not just a one-off activity? 
7. Is early treatment of the target condition effective? 
8. Do the objectives of the screening programme justify the costs? 
 
In fact, the target condition should be severe and frequent enough to justify screening. 
Morbidity, mortality and quality of life of those affected should be considered in judgement of 
the severity. The group of individuals eligible for screening is often selected by certain 
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demographic risk factors associated with the disease, e.g., age of onset of the condition of 
interest. For the purpose of screening the usefulness of a screening test is determined by 
test performance which includes sensitivity (the % of all affected individuals detected by a 
positive test) and specificity (the % of unaffected individuals with a negative test). Besides 
the advantages of screening in terms of timely – pre-symptomatic - detection of an adverse 
health condition, there are also associated problems, such as false-negative test results and 
undue anxiety following false-positive test results. A good screening programme is based on 
objective information on the potential benefits, as well as on the limitations of screening.  
 
From the early 70s Down syndrome screening by means of invasive prenatal tests was 
offered to women of advanced maternal age, i.e., from 36 years and above. With respect to 
Down syndrome, the Dutch Health Council committee concluded in 2007 in their report that 
on the basis of relatively good test properties, the presumed acceptance by the target group 
and feasibility of testing, the combined test was considered the best option for prenatal 
screening for Down syndrome. The combined test involves a blood test and nuchal 
translucency (NT) measurement by means of ultrasound, both conducted in the first trimester 
of pregnancy 23. The committee recommended the Minister of Health, Welfare and Sports to 
implement prenatal screening for Down syndrome in the Netherlands, thereby taking into 
account most criteria of Wilson and Jungner. In 2007, the Minister of health, Welfare and 
Sports granted formal permission for prenatal screening for Down syndrome and neutral tube 
defects (See also paragraph 1.5). Currently screening tests for aneuploidy and fetal 
malformations have been incorporated in the day to day obstetric practice in the Netherlands 
and other high-income countries 24. Before the test is conducted women need informed about 
the opportunity of testing and, where indicated, counselled about potential implications of 
testing including the advantages and disadvantages of screening, the likelihood of false 
positive and false negative results, invasive procedures and the subsequent consequences 
of abnormal findings. The cut-off point for increased risk is set at 1 in 200 25. In 2011 the first-
trimester screening test was expanded with the screening for trisomy 13 and 18 with the 
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same cut-off point off 1 in 200. Since April 2014 women at increased risk of trisomy 21, 13 or 
18 in the Netherlands are offered the Non-Invasive Prenatal Test (NIPT) next to the golden 
standard of invasive testing (chorionic villus sampling or amniocentesis) 26. In January 2015, 
the criterion of maternal age for prenatal testing has been abandoned. In the screening 
setting, only women at increased risk from the findings of the combined test, will be eligible 
for further testing.  
 
1.3 Ultrasound screening 
The use of ultrasound in the evaluation of pregnancy for both diagnostic and screening 
purposes is well established. Detection and assessment of a specific characteristic of the 
fetus and its association with an anomaly can be used as a feature for prenatal screening. 
The nuchal translucency is one of these features. It is a fluid layer in the posterior neck 
region between the fetal skin and extends for a variable distance over the head and neck. 
The thickness of this translucent area increases with the fetal crown-rump length (CRL) and 
can be visualized by ultrasound in the short time frame between the 11th and 14th week of 
gestation. An enlarged NT is defined as an NT above the 99th centile (3.5 mm or more ) and 
is associated with an increased prevalence of aneuploidy 27, particularly trisomy 21, but also 
with other abnormalities such as genetic syndromes and cardiac defects 28,29 .These 
observations and the term ‘nuchal translucency’ were published by Nicolaïdes et al. in 1992 
30. The assessment of risk of  trisomy 21 by maternal age and NT thickness was described in 
1998 by Snijders et al. and the Fetal Medicine Foundation First-trimester Screening Group  in 
a large multicenter study 31. About 80% of the affected pregnancies could thus be detected. 
Reliable screening performance is essential and depends first and foremost on the quality 
and reproducibility of the NT measurement 32-37. If an enlarged NT is detected the risk of 
other chromosomal anomalies is also increased. Of all the fetuses with an enlarged NT about 
20% will have a chromosomal abnormality. There is a clear interrelation between prevalence 
of chromosomal abnormalities and the increase in NT above the 99th centile 27. Trisomies 21, 
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18, 13 and Turner syndrome (45 X0) are the most frequently associated chromosomal 
anomalies found 38.  
To achieve higher rates of detection of Down syndrome and to further reduce the need for 
invasive testing, several strategies involving both first-trimester and second-trimester 
screening tests have been introduced 39. These include biochemical and sonographic 
markers for chromosomal abnormalities.  
Improvement of the performance of the combined test (see paragraph 1.5) may be achieved 
by the inclusion of other first-trimester sonographic markers, such as absence of the nasal 
bone, abnormal flow in the ductus venosus and across the tricuspid valve, and abnormal 
fronto-maxillary facial angel, in the algorithm for risk assessment 38,40-42. These makers, 
however, are not incorporated in the national screening programme for Down syndrome in 
the Netherlands. In some tertiary clinics these markers are used for women at intermediate 
risk who are reluctant to have invasive testing because of the inherent risk of miscarriage 
following amniocentesis or chorionic villus sampling. These markers could modify the risk 
derived  from the combined test, potentially resulting in a lower risk of Down syndrome 39. 
This strategy has an effect on the numbers of false positive test results from the combined 
test, presumably without jeopardizing the detection rate of Down syndrome. Two of these 
markers, Doppler of the ductus venosus en tricuspid valve, have proven to be more reliable 
in screening for congenital hearts defects. A normal sonographic examination, however, may 
provide false reassurance to women with a risk that is increased on the basis of first trimester 
combined test. Since April 2014 the Health Council of the Netherlands has approved the use 
of NIPT in a study setting in case of an increased risk for aneuploidy (trisomies 21, 13 or 18) 
of 1 in 200 or more 26. Second-trimester ultrasound examinations i.e. the so-called 20-weeks 
fetal anomaly scan, are often routinely performed to detect fetal anatomical abnormalities. 
The finding of a major anomaly or two or more minor structural malformations increases the 
likelihood of aneuploidy. A number of fetal structural abnormalities and isolated sonographic 
markers detectable on second-trimester sonographic examination have been associated with 
Down syndrome 39,43,44. These include intracardiac echogenic focus, ventriculomegaly, 
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increased nuchal fold, hyper echogenic bowel, mild hydronephrosis, short femur, short 
humerus,  absent or hypoplastic nasal bone and abnormal Doppler flow of the ductus 
venosus and tricuspid valve.   
In the Netherlands, combined first and second trimester screening tests are not used for the 
individual risk assessment since such approach is not included in the national screening 
programme for Down syndrome. However, in a euploid fetus with an NT above the 99th 
centile there is considerable evidence that shows an increased risk for structural anomalies, 
as especially with congenital heart defects 45-50. A detailed ultrasound examination at 14 
weeks and at 20 weeks however, is recommended in a contingently screening and 
diagnostic protocol 29. 
 
1.4 Biochemical screening 
In 1988, the value of maternal serum screening for Down syndrome was shown by Wald 51. 
Combinations of second-trimester maternal serum biochemical markers, such as alpha 
fetoprotein (AFP), human chorionic gonadotropin (hCG) and unconjugated estriol (uE3) in 
combination with a priori maternal age-specific risk of fetal aneuploidy, were used in the so 
called triple-test to refine patient-specific risk of trisomy 21. Limitations of this kind of serum 
screening include the limited detection rate (60%) for a 5% false positive rate and timing of 
the test, i.e., early second trimester. 
The value of the use of serum markers pregnancy-associated plasma protein-A (PAPP-A) 
and free ß-human chorionic gonadotropin (free β-hCG) in maternal serum screening in the 
first-trimester between 8-14 weeks was determined in a large study in which seven potential 
serum markers were compared. The test performance of free β-hCG and PAPP-A at 10 
weeks of pregnancy were similar to that of the triple-test at 15-22 weeks for a given maternal 
age 52-54. The levels of these two potential markers differed between affected and unaffected 
pregnancies. In affected pregnancies the median level of free beta-human chorionic 
gonadotropin (free β-hCG) was 1.79 times the median level for unaffected pregnancies. The 
other marker, PAPP-A, was 0.43 times the normal median 55-58. In a screening program for 
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Down syndrome, in which these serum markers were combined with maternal age, and with 
a cut-off level of 1:300, about 63% of the trisomy 21 affected pregnancies could be detected. 
Additionally low levels of first-trimester maternal serum PAPP-A are also shown to be 
predictive of other fetal chromosomal abnormalities, such as trisomy 13 and 18, triploidy and 
sex chromosome aneuploidy. Moreover, abnormal PAPP-A levels are associated with 
several adverse pregnancy outcomes including pre-eclampsia, fetal growth restriction, fetal 
demise and preterm birth among others 59. These issues are beyond the scope of the thesis. 
 
1.5 First-trimester combined screening. 
According the Dutch Health Council the most favorable screening test for Down syndrome in 
the first-trimester of pregnancy is the combination of the ultrasound measurement of NT with 
the placentally derived biochemical markers PAPP-A and free β-hCG 60. The so-called 
combined test is used as part of screening programme for trisomy 21, but also for other 
aneuploidies, of which approximately 90% can be identified. The combined test provides an 
individual risk estimate which is based on the combination of maternal age, NT and maternal 
serum free β-hCG and PAPP-A concentration at 11+0 to 13+6 weeks’ gestation. By this 
method it was shown that for a false positive rate of 5% the detection rate of trisomy 21 is 
about 76-90% 61-64, which is superior to the 44% achieved by maternal age alone and 60% by 
the second-trimester serum screening 54,60. In many countries world-wide an ever rising 
number of pregnant women have NT measurements, combined with biochemical tests, for 
the assessment of risk of Down syndrome 65-67. 
The test performance is dependent on a consistent and standardized determination of all 
parameters and is only applicable in a small time frame. The use of ultrasound to estimate 
gestational age improves the sensitivity and specificity of maternal serum screening 68,69. To 
allow for systematic changes in serum levels of PAPP-A and free β-hCG with changing 
gestational age, serum concentrations are converted into multiple of the normal median 
(MoM) at a given gestational age for both affected and non-affected pregnancies. By using 
the observed estimates of likelihood ratios (LRs) derived from maternal serum levels of the 
17 
 
markers, the individual risk of Down syndrome can be calculated using a mathematical 
model thereby taking into account the maternal age-related a priori risk of the woman. In fact, 
using Bayes theorem, the individual risk is obtained from the age-specific prevalence of 
Down syndrome and the various LRs derived from the observed estimates of the combined 
test 22.  
The overall prevalence of Down syndrome in a given population depends on the distribution 
of the maternal age, as the probability of trisomy 21 increases with the age of the pregnant 
woman 70. If the results of the first-trimester screening show an increased risk for Down 
syndrome an invasive diagnostic procedure is offered (chorionic villus sampling or 
amniocentesis) 25.  
In January 2007 the national program for prenatal screening for Down Syndrome has been 
implemented in the Netherlands 71. First-trimester screening by means of the combined test 
for the detection of Down syndrome) is made available  to all pregnant women (Health 
Council of the Netherlands) 23. In the Netherlands  the first-trimester screening test was in 
2010 extended with a risk assessment for Edward syndrome (trisomy 18) and Patau 
syndrome (trisomy 13) 72. 
 
Methodological issues of first trimester screening 
In both screening and diagnostic settings, the reliability of a test is a very important asset. 
Reliability is synonymous to reproducibility, repeatability, transferability, precision and 
consistency. These terms refer the degree of stability when a measurement is repeated 
under the same conditions. The extent to which a test is reliable is affected by the variation 
arising from three main sources (1) the examination (laboratory facilities or equipment, 
including software packages with the various algorithms used for risk calculation; the 
ultrasound machine), (2) the examiner (skills, concentration and time taken for the 
examination) and (3) the examined (characteristics). Lack of reliability may result in 
measurement errors 22.  
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In order to improve test performance of the combined test, several suggestions have been 
made, including adjusting the algorithm for ethnicity, mode of conception, smoking and 
obesity 73-75. 
Since two different software approaches are used for risk calculation (i.e., Fetal Medicine 
Foundation (FMF) and Perkin Elmer) the reference laboratory for The Netherlands, the RIVM 
lab introduced harmonization of test results in 2008. The first step in harmonization was 
informing the pregnant woman of her risk of down syndrome at the time of testing rather than 
her risk at term 76. This had minor implications for the cut-off level for invasive testing. The 
second step was reporting risks based on MoMs rather than biochemical findings. This had 
implications for FMF software-users, who needed upgraded software for risk assessment. 
Other issues for methodological quality include the required skills for measuring an accurate 
NT and the quality of ultrasound equipment, in terms of contrast and minimal spacial 
resolution including image processing algorithms derived from CRL for the calculation of 
gestational age, display and grey scale settings, the prognostic value of jugular sacs among 
others.   
 
1.6 Aim of this thesis 
In this thesis we present several studies which describe some methodological issues of first-
trimester screening for Down syndrome and two other chromosomal abnormalities (trisomies 
18 and 13) by using ultrasound markers and maternal serum markers and combinations of 
these markers in order to provide more insight in the day to day use of the first-trimester 
screening test. The overall objectives include the study of the effectiveness of first-trimester 
testing for Down syndrome in daily practice and to determine factors associated with the 
variation of test performance. 
The specific aims of this thesis include the answers to the following questions: 
1. Is there a difference in first trimester risk estimates for trisomy 21, as calculated 
by two different software packages used in the Netherlands? 
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2. Do the different methods of estimating gestational age affect reliability of first-
trimester screening for Down syndrome? 
3. What is  the impact of  laboratory manufacturing errors of the concentration of the 
pregnancy-associated plasma protein A (PAPP-A) on the test performance of first-
trimester screening (FTS) for Down syndrome?  
4. What is the prevalence of detectable jugular lymphatic sacs in a setting for first 
trimester screening of Down syndrome, and is there an influence of jugular? 
lymphatic sacs on the screening performance for chromosomal abnormalities? 
5. Is there an added value in incorporating additional first trimester markers in 
extensive risk assessment for aneuploidy screening in the first trimester?    
6. What is the prognostic value of differences in growth patterns of aneuploid fetuses 
(trisomy 21, 18, 13 and X0) during the late first trimester when compared euploid 
and aneuploid fetuses using 3D Virtual Reality (VR)? 
20 
 
References 
1. Down, JL. Observations on an ethnic classification of idiots. Lond Hosp Clin Rep 1866;3:259-
62. 
2. Roizen, NJ, Peterson, D. Down's syndrome. Lancet 2003;361:1281-9. 
3. Vis, JC, Duffels, MG, Winters, MM, Weijerman, ME, Cobben, JM, Huisman, SA, Mulder, BJ. 
Down syndrome: a cardiovasular petrspective. J Intellect Disabil Res 2009;53:419-25. 
4. Karlsson, B, Gustafsson, J, Hedov, G,Ivarsson, SA, Anneren, G. Thyroid dysfunction in 
Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1998;79(3):242-5. 
5. Freeman, SB, Taft, LF, Dooley, KJ, Allran, K, Sherman, SL, Hassold, TJ, Khoury, MJ, Saker, 
DM. Population-based study of congenital heart defects in Down syndrome. Am J Med Genet 
1998;80(3):213-7. 
6. Shott, SR, Joseph, A, Heithaus, DS. Hearing loss in children with Down syndrome. Int J 
Pediatr Otorhinolaryngol 2001;1(61/3):199-205. 
7. Caputo, AR, Reynolds, DR, Goel, AK, Wagner, RS, Guo, SQ. Down syndrome. Clinical review 
of ocular features. Clin Pediatr 1989;28(8):355-8. 
8. Tjio, JH, Levan, A. The chromosome number of man. Hereditas 1956;42:1-6. 
9. Lejeune, J, Turpin, R, Gautier, M. Chromosomic diagnosis of mongolism. Arch Fr Pediatr 
1959;16:962-3. 
10. Steele, MW, Berg WR.jr. Chromosome analysis of human amniotic-fluid cells. Lancet 
1966;1(7434):383-5. 
11. Valenti, C, Schutta, EJ, Kahaty, T. Prenatal diagnosis of Down's symdrome. Lancet 
1968;2(7561):200. 
12. Simoni, G, Brambati, B, Danesino, C, Rossella, F,Terzoli, GL, Ferrari, M, Fraccaro, M. 
Efficient direct chromosome analyses and enzyme determinations from chorionic villi samples in the 
first trimester of pregnancy. Hum Genet 1983;63(4):349-57. 
13. Alfirevic, Z, Mujezinovic F, Sundberg K. Amniocentesis and chorionic villus sampling for 
prenatal diagnosis. Cochrane Database of Systematic Reviews 2003. 
14. Caughey, AB, Hopkins LM, Norton ME. Chorionic villus sampling compared with 
amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynaecol 2006;108:612-6. 
21 
 
15. Mujezinovic, F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic 
villus sampling. A systematic review. Obstet Gynaecol 2007;110:687-94. 
16. Odibo, AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss 
rate after second-trimester genetic amniocentesis. Obstet Gynaecol 2008;111:589-95. 
17. Smidt-Jensen, S, Permin, M, Philip, J, Lundsteen, C,  Zachary, JM, Fowler, SE, Grüning, LK. 
Randomized comparison of amniocentesis and transabdominal and transcervical chorionic villus 
sampling. Lancet 1992;340:1237-44. 
18. Tabor, A, Madsen M, Obel E, Philip J, Bang J, Nørgaard-Pedersen B. Randomised controlled 
trail of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1:1287-93. 
19. van Gameren-Oosterom, HB, Buitendijk, SE, Bilardo, CM, van der Pal-de Bruin KM,, Van 
Wouwe, JP. Unchanged prevalence of Down syndrome in the Netherlands: results from an 11-year 
nationwide birth cohort. Prenat Diagn 2012;32:1035-40. 
20. de Graaf, G, Vis, JC, Haveman, M, van Hove, G, de Graaf, EA, Tijsen, JG, Mulder, BJ. Down 
Syndrome in the Netherlands, England/Wales and Ireland Past and Prospects; a demographic model 
for birth and population prevalence.  10th W0RLD DOWN SYNDROME CONGRESS. Dublin, Ireland 
2009. 
21. Wilson J, Jungner, G. Principles and practice of screening for disease Public Health Paper no 
34 WHO 1968. 
22. Peters, TJ, Wildschut, HIJ, Weiner, CP. Epidemiologic considerations in screening. In: 
Wildschut HIJ, Weiner, CP, Peters, TJ, ed. When to screen in Obstetrics and Gynaecology. 2nd ed. 
Philadelphia: Saunders Elsevier; 2006:1-14. 
23. Health Council of the Netherlands. Population Screening Act. Prenatal screening on Down's 
syndrome and neural tube defects.  Publication no 2004/06 ISBN  90-5549-519-0: Health Council of 
the Netherlands 2007. 
24. Wildschut, HI, Peters, TJ, Weiner, CP. Sreening in woman's health, with emphasis on fetal 
Down's syndrome, breast cancer and osteoporosis. Human reproduction Update 2006;12(5):499-512. 
25. Schielen, PC, Wildschut, HI, Loeber, JG. Down syndrome screening: determinig the cutoff 
level of risk for invasive testing. Prenat Diagn 2009;29:190-2. 
26. Health Council of the Netherlands. NIPT: the dynamics and ethics of prenatal screening. 
Publication no. 2013/34. Health Council of the Netherlands 2013. 
22 
 
27. Kagan, KO, Avgidoe, K, Molina, FS, Gajewska, K, Nicolaides, KH. Relation between increased 
fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 2006;107:6-10. 
28. Bilardo, CM, Timmerman, E, Pajkrt, E, van Maarle, M. Increased nuchal translucency in 
euploid fetuses--what should we be telling the parents? Prenat Diagn 2010;30:93-102. 
29. Bakker, M, Pajkrt, E, Bilardo, CM. Increased nuchal translucency with normal karyotype and 
anomaly scan: what next? Best Pract Res Clin Obstet Gynaecol 2014;28:355-66. 
30. Nicolaides, KH, Azar, G, Snijders, RJ, Gosden, CM. Fetal nuchal oedema: associated 
malformations and chromosomal defects. Fetal Diagn Ther 1992;7(2):123-31. 
31. Snijders, RJ, Noble, P, Sebire, N, Souka, A, Nicolaides, KH. UK multicentre project on 
assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 
weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 
1998;352(9125):343-6. 
32. Pandya, PP, Snijders, RJ, Johnson, SP, De Lourdes Brizot, M, Nicolaides, KH. Screening for 
fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. 
Br J Obstet Gynaecol 1995;102 (12):957-62. 
33. Pajkrt, E, Mol, BW, Boer, K, Drogtrop, AP, Bossuyt, PM, Bilardo, CM. Intra- and interoperator 
repeatability of the nuchal translucency measurement. Ultrasound Obstet Gynaecol 2000;15(4):297-
301. 
34. Abele, H, Hoopman, M, Wright, D, Hoffmann-Poell, B, Huetelmaier, M, Pintoffl, K, Wallwiener, 
D, Kagan, KO. Intra- and interoperator reliability of manuel and semi-automated measurement of fetal 
nuchal translucency by sonographers with different levels of experience. Ultrasound Obstet Gynecol 
2010;36:417-22. 
35. Abele, H, Hoopman, M, Grischke, EM, Wallwiener, D, Kagan, KO. Effect of deviation from the 
mid-saggital plane on the measurement of fetal nuchal translucency. Ultrasound Obstet Gynecol 
2010;35:525-9. 
36. Kagan, KO, Wright, D, Etchegaray, A, Zhou, Y, Nicolaides, KH. Effect of deviation of nuchal 
translucency measurementson the performance of screenin for trisomy. Ultrasound Obstet Gynecol 
2009;33:657-64. 
37. Cuckle, H, Platt, LD, Thornburg, LL, Bromley, B, Fuchs, K, Abuhamad, A, Benacerraf, B, 
Copel, JA, Depp, R, D'Alton, M, Goldberg, J, Okeeffe, D, Spitz, J, Toland, G, Wapner, R; the Nuchal 
23 
 
Translucency Quality Review Program of the Perinatal Quality Foundation. Nuchal Translucency 
Quality Review (NTQR) Program: First One and Half Million Results. Ultrasound Obstet Gynecol 
2014.  doi: 10.1002/uog.13390. [Epub ahead of print] 
38. Nicolaides, KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15 
39. Driscoll, DA, Gross, S. Clinical practice. Prenatal screening for aneuploidy. N Eng J Med 
2009;360:2556-62. 
40. Maiz, N, Valencia, C, Kagan, KO, Wright, D, Nicolaides, KH. Ductus venosus Doppler  in 
screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound 
Obstet Gynecol 2009;33:512-7. 
41. Kagan, KO, Valencia, C, Livanos, P, Wright D, Nicolaides, KH. Tricuspid regurgitation in 
screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. 
Ultrasound Obstet Gynecol 2009;33:18-22. 
42. Borenstein, M, Persico, N, Kagan, KO, Gazzoni, A, Nicolaides, KH. Frontomaxillary facial 
angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 2008;32:5-11. 
43. Agathokleous, M, Chaveeva, P, Poon, LC, Kosinski, P, Nicolaides, KH. Meta-analysis of 
second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2012;41:247-61. 
44. Benacerraf, B. The history of the second-trimester sonographic markers for detecting fetal 
Down syndrome, and their current role in obstetric practice. Prenat Diagn 2010;30:644-52. 
45. Souka, AP, Von Kaisenberg, CS, Hyett, JA, Sonek, JD, Nicolaides, KH. Increased nuchal 
translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-21. 
46. Bilardo, CM, Müller, MA, Pajkrt, E, Clur, SA, van Zalen, MM, Bijlsma, EK. Increased nuchal 
translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet 
Gynecol 2007;30:11-8. 
47. Hyett, JA, Perdu, M, Sharland, GK, Snijders, RS, Nicolaides, KH. Increased nuchal 
translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet 
Gynecol 1997;10:242-6. 
48. Clur, SA, Mathijssen, IB, Pajkrt, E, Cook, A, Laurini, RN, Ottenkamp, J, Bilardo, CM. Structural 
heart defects associated with an increased nuchal translucency: 9 years experience in a referral 
centre. Prenat Diagn 2008;28:347-54. 
24 
 
49. Westin, M, Saltvedt, S, Almström, H, Grunewald, C, Valentin, L. By how much does increased 
nuchal translucency increase the risk of adverse pregnancy outcome in chromosomally normal 
fetuses? A study of 16,260 fetuses derived from an unselected pregnant population. Ultrasound 
Obstet Gynecol 2007;29:150-8. 
50. Wald, NJ, Morris, JK, Walker, K, Simpson, JM. Prenatal screening for serious congenital heart 
defects using nuchal translucency: a meta-analysis. Prenat Diagn 2008;28:1094-104. 
51. Wald, NJ, Cuckle, HS, Densem, JW, Nanchahal, K, Royston, P, Chard, T, Haddow, JE, 
Knight, GJ, Palomaki, GE, Canick, JA. Maternal serum screening for Down's syndrome in early 
pregnancy. BMJ 1988;297:883-7. 
52. Wald, NJ, George, L, Smith, D, Densem, JW, Petterson, K. Serum screening for Down's 
syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. 
Br J Obstet Gynaecol 1996;103(5):407-12. 
53. Canick, JA, Kellner, LH. First trimester screening for aneuploidy: serum biochemical markers. 
Semin Perinatol 1999;23(5):359-69. 
54. Yaron, Y, Mashiach, R. First-trimester biochemical screening for Down syndrome. Clin 
Perinatol 2001;28(2):321-31. 
55. Brambati, B, Macintosh, MC, Teisner, B, Maquiness, S, Shrimanker, K, Lanzani, A, Bonacchi, 
I, Tului, I, Chard, T, Grunzinskas, JG. Low maternal serum levels of pregnancy associated plasma 
protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet 
Gynaecol 1993;100(4):324-6. 
56. Brambati, B, Tului, L, Bonacchi, I, Shrimanker, K, Suzuki, Y, Grundzinskas, JG. Serum PAPP-
A and free beta-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 
1994;14(11):1043-7. 
57. Macintosh, MC, Ile, R, Teisner, B, Sharma, K, Chard, T, Grunzinskas, JG, Ward, RH, Muller, 
F. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, 
markers for fetal Down syndrome at 8-14 weeks. Prenat Diagn 1994;14(3):203-8. 
58. Forest, JC, Massé, J, Moutquin, JM. Screening for Down syndrome during first trimester: a 
prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma 
protein A. Clin Biochem 1997;30(4):333-8. 
25 
 
59. Spencer, CA,  Allen, VM, Flowerdew, G, Dooley, K, Dodds, L. Low levels of maternal serum 
PAPP-A in early pregnancy and the risk of adverse outcomes. Prenat Diagn 2008;28:1029-36. 
60. Gekas, J, Gagné, G, Bujold, E, Douillard, D, Forest, JC, Reinharz, D, Rousseau, F. 
Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness 
analysis of computer simulation. BMJ 338:b138 doi: 101136/bmjb138 2009. 
61. Wright, D, Kagan, KO, Molina, FS, Gazzon, A, Nicolaides, KH. A mixture model of nuchal 
translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynaecol 
2008;31:376-83. 
62. Nicolaides, KH, Spencer, K, Avgidou, K, Faiola, S, Falcon, O. Multicenter study of first-
trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact 
of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynaecol 
2005;25:221-6. 
63. Nicolaides, KH. Screening for chromosomal defects. Ultrasound Obstet Gynaecol 
2003;21:313-21. 
64. Wortelboer, EJ, Koster, MP, Stoutenbeek, Ph, Loeber, JG, Visser, GH, Schielen, PC. First-
trimester Down syndrome screening performance in the Dutch population; how to achieve further 
improvement? Prenat Diagn 2009;29(6):588-92. 
65. Zoppi, MA, Ibba, RM, Putzolu, M, Floris, M, Monni, G. Assessment of risk for chromosomal 
abnormalities at 10-14 weeks of gestation by nuchal translucency and maternal age in 5,210 fetuses 
at a single centre. Fetal Diagn Ther 2000;15(3):170-3. 
66. Spencer, K, Spencer, CE, Power, M, Dawson, C, Nicolaides, KH. Screening for chromosomal 
abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop 
clinic: a review of three years prospective experience. Br J Obstet Gynecol 2003;110(3):281-6. 
67. Muller, F, Benatter, C, Audibert, F, Roussel, N, Dreux, S, Cuckle, H. First-trimester screening 
for Down syndrome in France combining fetal nuchal translucency measurement and biochemical 
markers. Prenat Diagn 2003;23(10):833-6. 
68. Benn, PA, Borgida, A, Horne, D, Briganti, S, Collins, R, Rodis, J. Down syndrome and neural 
tube defect screening: the value of using gestational age by ultrasonography. Am J Obstet Gynecol 
1997;176:1056-61. 
26 
 
69. van Heesch, PN, Struijk, PC, Laudy, JAM, Steegers, EA, Wildschut, HI. Estimating the effect 
of gestational age on test performance of combined first-trimester screening for Down syndrome: a 
preliminary study. J Perinat Med 2010;38:305-9. 
70. Morris, JK, Mutton, DE, Alderman, E. Revised estimates of the maternal age specific live birth 
prevalence of Down's syndrome. J Med Screen 2002;9:2-6. 
71. Schielen, PC, van Leeuwen-Spruijt, M, Belmouden, I, Elvers, LH, Jonker, M, Loeber, JG. 
Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. 
Prenat Diagn 2006;26:711-8. 
72. Kagan, KO, Wright, D, Valencia, C, Maiz, N, Nicolaides, KH. Screening for trisomies 21, 18 
and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free b-hCG and pregnancy-
associated plasma protein-A. Hum Reprod 2008;23 (9):1968-75. 
73. Cowans, NJ, Spencer, K. Effect of gestational age on first trimester maternalserum prenatal 
screening correction factors for ethnicity and IVF conception. Prenat Diagn 2012;21. 
74. Kagan, KO, Wright, D, Spencer K, Molina, FS, Nicolaides, KH. First-trimester screening for 
trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: 
impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493-502. 
75. Spencer, K, Cowans,NJ. Correction of first trimester biochemical aneuploidy screening 
markers for smoking status: influence of gestational age, maternal ethnicity and cigarette dosage. 
Prenat Diagn 2012:1-8. 
76. Koster, MP, Heetkamp, KM, de Miranda, E, Schielen, PC. Comparison of risk calculation 
approaches in a screening programme for Down syndrome. J Perinat Med 2012;40:259-63. 
 
27 
 
Part 1    
 
The biochemical issues in first-trimester screening 
  
28 
 
 
 
 
 
 
29 
 
Chapter 2 
Estimating gestational age affects test performance 
of combined first-trimester screening for Down 
syndrome: a preliminary study 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Peter N.A.C.M. van Heesch, Pieter C. Struijk, Jacqueline A.M. Laudy,  
Eric A.P. Steegers, Hajo I.J. Wildschut 
J Perinat Med. 2010; 38(3): 305-309  
30 
 
Abstract 
Objective: To establish how different methods of estimating gestational age (GA) affect 
reliability of first-trimester screening for Down syndrome.   
Methods: Retrospective single-center study of 100 women with a viable singleton 
pregnancy, who had had first-trimester screening. We calculated multiples of the median 
(MoM) for maternal-serum free beta human chorionic gonadotropin (free β-hCG) and 
pregnancy associated plasma protein-A (PAPP-A), derived from either last menstrual period 
(LMP) or ultrasound-dating scans. 
Results: In women whit a regular cycle, LMP-derived estimates of GA were two days longer 
(range -11 to18), than crown-rump length (CRL)-derived estimates of GA whereas this 
discrepancy was more pronounced in women who reported an irregular cycle, i.e., six days 
(range -7 to 32). Except for PAPP-A in the regular-cycle group, all differences were 
significant. Consequently, risk estimates are affected by the mode of estimating GA. In fact, 
LMP-based estimates revealed ten ‘screen-positive’ cases compared to five ‘screen-positive’ 
cases where GA was derived from dating-scans. 
Conclusion: Provided fixed values for nuchal translucency are applied, dating-scans reduce 
the number of false screen-positive findings on the basis of biochemical screening. We 
recommend implementation of guidelines for Down syndrome screening based on CRL-
dependent parameters of GA. 
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Introduction 
It is widely acknowledged that first-trimester screening is currently a sensitive method of 
screening for Down syndrome and other chromosomal abnormalities1-2. The combined first-
trimester screening test is typically based on information of maternal age, the sonographic 
findings of the nuchal translucency (NT) thickness and by the laboratory findings of two 
biochemical markers in maternal serum, i.e. free beta human chorionic gonadotropin (free β-
hCG) and pregnancy associated plasma protein-A (PAPP-A). The test performance of the 
NT-measurement is optimal in the short time frame from 11+0 to 14 weeks’ gestation, which 
corresponds with a crown-rump length (CRL) of 45 to 84 mm1.  
The Fetal Medicine Foundation (FMF) introduced the one step clinic for assessment of risk 
(OSCAR) approach for the detection of Down syndrome and other chromosomal 
abnormalities by combined biochemical maternal serum and fetal ultrasound testing at a 
single visit3-6. This approach involves a 1-h visit, which includes the testing of the biochemical 
markers in maternal serum, the NT-examination and subsequent counseling about the 
individual risk for Down syndrome. An alternative strategy used for the combined first-
trimester screening test for Down syndrome is the so-called two-step approach or 
consecutive combined test which requires two separate visits. For the same false-positive 
rates, the reported detection rates of the two-step approach are seemingly better than those 
of the OSCAR approach7-9. These studies have demonstrated that the combined first-
trimester screening test performs best when the maternal blood sample is taken at 10 
weeks10 and the measurement of NT is performed at 12 weeks’ gestation11. With the 
introduction of enhanced sonographic technology it is nowadays also possible to detect of a 
number of major structural malformations during the first-trimester screening scan12-13.  
Since all three markers in the first-trimester screening test for Down syndrome vary with GA, 
the estimates of free β-hCG and PAPP-A are converted to a multiple of the expected normal 
median (MoM) to adjust for the effect of GA, while delta-values for NT are derived from 
information of CRL at the time of NT measurement. In the two-step approach the 
ultrasonically derived CRL measurement (dating scan) is not necessarily available at the time 
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of maternal blood sampling. In fact, the blood sample is sent to the laboratory with 
information on dating based either on the last menstrual period (LMP) or on sonographic 
measurement (CRL) at the first or booking visit. The NT is measured at a subsequent visit. 
This is done simultaneously with a CRL-measurement. The GA thus derived does not 
necessarily corroborate with that derived from LMP or the dating scan at the booking visit. 
The aims of this preliminary study are: (1) to determine the difference between the GA 
estimate on the basis of available information of the LMP and the GA estimate on the basis 
of the ultrasound CRL-findings at booking, and (2) to assess the impact of these two modes 
of estimating GA on risk estimates for Down syndrome which are derived from the two-step 
approach by the combined first-trimester screening test.   
 
Materials and Methods 
From November 2005 to January 2006, each eligible woman attending the out-patient clinic 
at the Division of Obstetrics and Prenatal Medicine at Erasmus University Medical Center, 
Rotterdam, the Netherlands, was informed about our study. Women were excluded from the 
study if their index pregnancy was complicated by multiple-pregnancy, diabetes or high 
blood-pressure. They were also excluded if they had a history of pre-eclampsia, preterm birth 
or intra-uterine growth restriction. All participants in this study gave informed consent. 
At the booking visit, which typically takes place between 8+4 to 13+6 weeks’ gestation based 
on LMP dating, background information of the study participants was collected.  The 
menstrual cycle of 28 (± 4) days was considered regular.  
At the booking visit, a blood sample was taken and an ultrasound scan was done to 
determine CRL. This so-called dating scan was carried out either abdominally (C5-2 probe) 
or transvaginally (C8-4V probe), using a Philips Envisor C-HD (Philips Medical Division, 
Eindhoven, the Netherlands). GA based on CRL was determined using the formula obtained 
from Robinson and Flemming14. The NT-measurement, and additional fetal-biometry, was 
performed at the subsequent visit for the first-trimester screening for Down syndrome, which 
typically takes place between 11+0 and 14 weeks (CRL 45-84 mm.). NT-measurements were 
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carried out in accordance with the FMF protocol15-17, either abdominally (C5-2 probe) or 
transvaginally (C8-4V probe), using a Philips iU22 (Philips Medical Division, Eindhoven, the 
Netherlands). 
The maternal serum samples were analyzed with the Auto-DELFIA analyzer (Perkin Elmer 
Life Science, Boston, MA, USA) and commercially available kits. Analysis was done at the 
laboratory of Star Medical Diagnostic Center in Rotterdam, one of the six regional 
laboratories for Down syndrome screening in the Netherlands. Maternal-weight-corrected 
MoM values of the biochemical markers free β-hCG and PAPP-A were derived from the 
concentrations adjusted for GA at sampling date; this was on the basis of the available 
information on dating (LMP or ultrasound) and was related to the medians provided by the 
Dutch reference institute for first-trimester serum screening, Diagnostic Laboratory for 
Infectious Diseases and Perinatal Screening, National Institute for Public Health and 
Environment (RIVM), Bilthoven, the Netherlands.  
Adjusted for maternal weight, two different MoM-values of the biochemical parameters were 
calculated. One was calculated from information of the GA derived from the LMP at sampling 
date, whereas the other was calculated from information of the GA on the basis of CRL-
finding at booking. The calculations of the maternal-weight-corrected MoMs of the 
biochemical markers were done using the LifeCycle-Elips software (Perkin Elmer Life 
Science, Boston, MA, USA). For the final risk estimation, the ultrasound data and the results 
of the maternal serum analysis of the free β-hCG and  
PAPP-A were combined in the FMF-module in an obstetrical software database (Astraia 
version 1.17.69, Astraia Software GmbH, München, Germany). The NT was measured at a 
second visit. The delta-values for NT were derived from information on CRL-findings at the 
time of NT measurement. The software (Astraia version 1.17.69) used in this study, does not 
allow input of LMP data to calculate the risk on the basis of NT.  
In the Netherlands, the threshold for ‘screen positive’ and for the subsequent offer of invasive 
diagnostic testing, i.e. chorionic villus sampling (CVS) or amniocentesis is set at 1 in 200 at 
the time of the risk assessment 18. Since all participants were recruited from the obstetric  
34 
 
Table 1: General characteristics grouped by women who reported a regular and those who reported an irregular 
cycle. Differences between group medians are tested for statistical significance by applying the Mann-Whitney U 
test. 
    
 Regular cycle N=70 Irregular cycle N=30 M W-U 
 Median (min, max) Median (min, max) P value 
    
Maternal age (years) 36 (27, 42) 35.5 (25, 42) 0.123 
GA at intake (days) 74 (53, 99) 76.5 (63, 96) 0.149 
GA intake [CRL] (days) 72 (53, 97) 71.5 (55, 91) 0.491 
CRL (dating scan) (mm) 36.4 (14.0, 82.0) 35.5 (15.8, 69.4) 0.480 
GA  at NT CRL (days) 87 (77, 97) 88 (79, 97) 0.363 
CRL at NT (mm) 60.8 (41.3, 81.1) 63.4 (46.5, 82.3) 0.417 
NT (mm) 1.6 (0.9, 2.9) 1.7 (1.2, 3.5) 0.335 
fβ-hCG (ng/ml) 44.7 (7.9, 199.9) 55.5 (18.5, 272.5) 0.118 
MoM fβ-hCG [LMP] 1.0 (0.2, 4.6) 1.5 (0.4, 9.0) 0.002* 
MoM fβ-hCG [CRL] 0.9 (0.2, 4.3) 1.2 (0.4, 9.4) 0.020* 
PAPP-A (mU/l) 866 (125, 4319) 889 (224, 4591) 0.285 
MoM PAPP-A  [LMP] 1.0 (0.1, 5.1) 0.9 (0.2, 3.4) 0.545 
MoM PAPP-A  [CRL] 1.0 (0.2, 3.4 1.1 (0.3, 3.2) 0.323 
 
* Statistically significant at the level p < 0.05, M-W U; Mann-Whitney U test, GA; Gestational Age, CRL; crown-
rump length, NT; Nuchal Translucency, β-hCG  free beta-human chorionic gonadotropin, PAPP-A; Pregnancy 
associated plasma protein-A, [LMP]; dating on the basis of last menstrual period, [CRL]; dating on the basis of 
crown-rump length measurement, MoM; Multiple of the Median. 
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outpatient-clinic of our university hospital, a complete follow-up of the pregnancy and delivery 
was available.  
A distinction was made between women who were reported to have a regular cycle and 
those reported to have an irregular menstrual cycle. To assess whether the observations 
from these two groups came from the same distribution, the Mann-Whitney U test was 
applied. Like the paired differences between dating on the basis of LMP and CRL, the 
biochemical-variables expressed as MoM-values on the basis of these two dating methods 
are presented as medians and ranges.  
The statistical analyses were performed using the SPSS statistical package for Windows 
release 15.1 (SPSS Inc. Chicago, IL). Statistical significance was defined as a p value < 
0.05. 
 
Results  
In our preliminary study we included a total of 100 consecutive women with a viable singleton 
pregnancy. Median maternal age of all the women in the study population was 36 years 
(range 18 to 43 years). The study population was mainly white, i.e. 85% Caucasian, 8% 
Asian and 7% Afro-Caribbean. Seventy percent of them reported having a regular cycle, 
whereas the remainder had an irregular cycle. The background characteristics of the two 
groups are shown in Table 1. Except for free β-hCG there were no statistically significant 
differences in background characteristics between the two groups. The median GA at 
delivery was 279 days (range 238-297 days) or 39+6 weeks (range 34+0 – 42+3 weeks) and 
the median birth weight was 3568 grams (range 2010-5080 grams). None of the pregnancies 
was complicated by pre-eclampsia or diabetes. There was one case of prenatal diagnosed 
placental confined trisomy 1619 and one case of a postnatal diagnosis of atresia of the 
pulmonary artery.  
Table 2 presents the paired differences resulting from the two dating methods for GA, and 
the MoM-values for the free β-hCG and PAPP-A. The differences are summarized as 
medians and ranges for both regular and irregular menstrual-cycle groups.  
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Table 2 
The paired differences of gestational age and the MoM values for the free β-hCG and PAPP-A as determined by 
dating on the basis of LMP and CRL (dating scan). They are presented as medians and range in the regular and 
irregular menstrual cycle groups.  
   
 Regular cycle N=70 Irregular cycle N=30 
 Median (min, max) P value Median (min, max) P value 
     
GA[CRL]– GA[CRL] (days) 
 
2 (-11, 18) 0.006* 6 (-7, 32) 0.001* 
 Free β-hCG   
MoM[LMP] – MOM[CRL[ 
  
0.06 (-0.86, 1.08) 0.008* 0.18 (-0.51, 2.23) 0.003* 
 PAPP-A   
MoM[LMP] – MOM[CRL] 
  
-0.14 (-0.93, 3.32) 0.141 -0.23 (-2.18, 0.76) 0.006* 
 
* Statistically significant at the level of p < 0.05 as determined by the Wilcoxon signed rank test. GA; Gestational 
Age, MoM; Multiple Of the Median, free β-hCG  free beta-human chorionic gonadotropin, PAPP-A; Pregnancy 
Associated Plasma Protein-A, [LMP]; dating on the basis of last menstrual period, [CRL]; dating on the basis of 
crown-rump length. 
 
In women who reported to have a regular cycle, there was a small but statistically significant 
difference of two days (range -11 to 18); women who reported an irregular cycle had a more 
pronounced difference of six days (range -7 to 37). The scatter plot showing GA on the basis 
of LMP vs. the GA on the basis of CRL is presented in Figure 1. As the expected normal-
medians for the biochemical markers are specific to GA, the differences resulting from the 
two dating modes obviously influence the estimates of the MoM-values and the subsequent 
risk estimates. In the irregular-cycle group the MoM of the free β-hCG is statistically 
significantly higher for both LMP-dating and CRL-dating compared to the regular cycle group.  
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Table 3. 
Agreement between test results for the risk to detect a fetus with Down syndrome in a group of 100 pregnant 
women on the basis of dating from LMP and CRL. 
 
Test results* 
 
 
CRL based LMP based N 
 
- 
 
- 
 
89 
- + 6 
+ - 1 
+ + 4 
 
* The test is considered positive if the calculated risk is greater than 1 in 200. 
 
 
Table 3 shows the potential impact on risk-estimation for Down syndrome. Four women were 
‘screen positive’, independent of the method used.  
Calculations of the MoM-values for free β-hCG and PAPP-A on the basis of ultrasound 
dating by CRL at booking showed that five women were ‘screen positive’.  If dating was on 
the basis of LMP, ten women were ‘screen positive’. This result indicates that the method of 
dating has a considerable effect on the test result of the combined first-trimester screening 
test for Down syndrome. 
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Figure 1. 
 
 
 
 
 
 
Figure 1: Scatter plot is showing gestational age (GA) on the basis of last menstrual period (LMP) versus 
gestational age on the basis of crown-rump length (CRL) using the formula obtained from Robinson and 
Flemming 1975. The diagonal line represents the line of equality. Open circles (○) and dotted linear regression 
line (----) represent the group that reported an irregular menstrual cycle:  GA = 0.769 ∙ GA-CRL (days) + 18.5 (R2 
= 0.622, p<0.001) and filled circles (●) and dotted /dashed linear regression line (▪▬▪) represent the group that 
reported a regular menstrual cycle: GA = 0.476 ∙ GA-CRL (days) + 43.9 (R2 = 0,406, p<0.001). 
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 Discussion 
This preliminary study was undertaken to evaluate the optimal mode of GA assessment for 
the calculation Down syndrome risk by first-trimester screening using a two-step approach. 
This study shows that correct dating of the pregnancy is crucial. If the booking visit is not 
accompanied by an ultrasound dating-scan, erroneous risk assessment might result, 
undermining the test performance of the two-step approach. Considerable differences in 
pregnancy dating, ranging from -11 to 18 days, were found in our study population (Figure 1), 
even in women who reported a regular menstrual cycle.  
Because the missing or the lack of reliable information, the LMP cannot be used in about 
40% of the women 20. Hence, dating by means of ultrasound in early pregnancy has become 
an accepted way of estimating GA. In fact, recent results from studies involving large cohorts  
of pregnant women support the hypothesis that early dating scan provide more reliable 
information on GA than the first day of the LMP 21-22. The CRL has been proven to be a 
reliable measurement for determining the GA of a chromosomal normal fetus 23-24. 
In the Netherlands first-trimester screening is the prevailing risk assessment strategy for 
Down syndrome 25 where  likelihood ratios are obtained from delta-NT findings which are 
derived from CRL-dating at the time of NT measurement. As CRL does not necessarily 
reflects true GA, the risk calculation derived from CRL at NT measurement, might be wrong. 
Theoretically, this is applicable for fetuses with chromosomal abnormalities, as they are 
typically growth restricted, even in the first trimester of pregnancy 19, 26. Given an absolute 
value of NT-thickness, the smaller CRL in fetuses with chromosomal abnormalities will 
generate potentially a higher risk if gestational length is spuriously adjusted for the CRL-
finding. In fact spuriously adjusting the GA on the findings of a “small” CRL, a fixed NT will 
have a positive impact on the detection rate. It is well established that the interpretation of 
absolute values of NT is CRL dependent.  
As the values of NT, free β-hCG and PAPP-A are GA-specific, accurate assessment of GA is 
essential for the proper interpretation of the combined first-trimester screening test. In this 
context, national guidelines should be set for the choice of the reference curve and for the 
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accurate measurement of CRL, irrespective of GA. Even in a small highly developed country, 
such as the Netherlands, there is neither standardization in the software used to calculate 
risk for Down syndrome 27 nor in CRL reference curves 28. From the findings of our study we 
recommend the implementation of guidelines for a Down syndrome screening that is based 
on CRL rather than LMP for GA 28.  We postulate that reduction in ‘screen positive’ test 
results might considerably decrease unnecessary invasive procedures, and hence in 
iatrogenic loss of pregnancy when first-trimester screening for Down syndrome is determined 
explicitly on information of CRL. However, our study sample was too small to substantiate 
this notion. For this reason, it is important to estimate the test performance of this screening 
policy with large population-based data. 
In conclusion, provided fixed values for NT are applied, dating scans reduce the number of 
‘screen-positive’ findings on the basis of biochemical screening. We recommend 
implementation of guidelines for Down syndrome screening-policy, which is based on CRL-
dependent rather than LMP-dependent parameters of GA. 
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lack of agreement between risk calculation methods 
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Abstract 
Objective:  To call attention to differences in first trimester risk estimates for trisomy 21, as 
calculated by two different software packages.   
Methods: A total of ninety-four pregnant women who had a first trimester risk assessment for 
trisomy 21 that was based on maternal age, biochemical analysis and a nuchal translucency 
(NT) measurement. Two commonly used software packages were used for the estimation of 
individual risks (i.e. Wallac-Perkin-Elmer£software and Fetal Medicine Foundation£ 
software).  
Results: Risk estimates derived from each software programme were strikingly different. In 
each case the discrepancy in reported magnitude of risk resulted from disparities between 
the two calculation methods for the assessment of the individual risk for trisomy 21. The 
disparities in risk estimates can be explained by significant differences in reported likelihood 
ratio’s for biochemical analyses (p=0.01), NT measurements (p<0.0001) and both screening 
parameters combined (p=0.003).   
Conclusion:  It is illustrated that the lack of agreement between these risk calculation 
methods could give rise to major counselling problems. In order to avoid confusion, there is a 
need for estimating individual risks of trisomy 21 in a standardized way. It is proposed to 
select a set of parameters that have a proven track record as judged by detection rates and 
false positive rates and then use that set exclusively, while simultaneously monitoring its 
performance.   
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Introduction 
Worldwide an ever-increasing number of women have nuchal translucency (NT) 
measurements in their pregnancy, often together with biochemical tests, for the assessment 
of risk of trisomy 21 1-4. While policymakers, insurance companies and medical organizations 
in many countries are still reluctant to endorse screening of all pregnant women, patient 
autonomy and self-determination has led to the situation where almost every pregnant 
woman in Europe will have the opportunity to be screened for trisomy 21, either because it is 
offered or because she asks for it. Women who decide to take up non-invasive testing will be 
informed about their individual risk of trisomy 21. Information on the risk estimate could help 
them, and their partners, to make decisions about the need for invasive diagnostic testing 
(amniocentesis or chorionic villus sampling) in order to obtain the definite fetal karyotype. 
Women’s decisions to take up invasive testing depend on the magnitude of the reported risk 
3. In fact, there is a complete trust among caregivers and the public in the reliability of risk 
calculations that are produced on the basis of the various parameters of non-invasive testing, 
such as maternal age, gestational age, nuchal translucency (NT) measurements and 
biochemical serum markers. However, the individual perception of what may constitute ‘high 
risk’ of ‘low risk’ varies greatly since the individuals’ assessment of risks is mostly determined 
by emotions rather than facts 5. In the Netherlands, a screening-derived risk estimate of  >1 
in 200 6 (i.e., odds for an infant with trisomy 21 born alive at term) is used as an objective 
criterion for classifying women as ‘high risk’; invasive testing for fetal karyotyping is 
subsequently offered. This cut-off level, however, could have a great emotional impact on the 
woman as was illustrated recently by French authorities who reported that women have been 
known to seek pregnancy termination without waiting for the confirmation of the possible fetal 
- chromosomal - defect, a practice called “precautionary eugenics” (eugénisme de 
précaution) 7. Alternatively, when the combined first trimester screening test result is 
compatible with a low risk of trisomy 21, women may decide to refrain from invasive testing, 
thereby avoiding iatrogenic fetal loss.  
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For individual risk estimations several software programs are commercially available. In our 
department, risk estimates derived from biochemical parameters are given - for logistic 
reasons - by the National Institute for Public Health and the Environment (RIVM), using 1T-
risks version 1.7 Wallac-Perkin-Elmer£ software, while risk estimates derived from NT 
findings are given by Fetal Medicine Foundation (FMF£) software, which is directly 
accessible in our department. Individual numerical first trimester risk estimates, however, are 
not always unequivocal as we have witnessed several times in our department. At times, the 
combined test results reported by the RIVM yielded a combined risk estimate that was below 
the cut-off value for invasive testing, while that derived from the FMF£software was above 
this threshold value or vice versa. Both caregivers and couples felt at loss with these 
discrepant test results. Concern about the lack of agreement between the risk estimation 
methods has led us to analyse differences between the reported findings derived from the 
two software packages.   
 
Methods 
To investigate the differences in risk estimates derived from two widely used software 
packages, risk of trisomy 21 was assessed in a total of 94 women who consecutively visited 
the out-patient department of obstetrics and prenatal diagnosis at our University Hospital. 
Each woman had a viable, singleton pregnancy. Risk estimates were derived in the first 
trimester of pregnancy from the woman’s age at the time of testing, levels of first trimester 
biochemical serum markers (i.e., maternal serum free beta-human chorionic gonadotropin 
(fßhCG) and pregnancy-associated plasma protein-A (PAPP-A)), NT measurements, 
gestational age and relevant medical history. Blood sampling was done from 8 to 14 week’s 
gestation, in almost all cases prior to NT measurement in order to be able to discuss the 
results together with the findings of the NT measurement. Trained sonographers who all 
were certified by the FMF conducted NT measurements on ATL 3000 machines. All NT 
measurements were performed between 11 and 14 weeks of gestation.  
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The compared software programmes included 1T-risks version 1.7 Wallac-Perkin-Elmer£, 
that is based on an algorithm derived from data published by Cuckle & Van Lith 8 and Wald 
and Hackshaw 9, and the FMF£ software that is based on an algorithm derived from data 
published by Spencer et al 10 and Snijders et al. 11.  The Wilcoxon signed-rank sum test was 
used to compare the interrelations between the two sets of observations (SPSS inc. version 
12.01, Chicago, Ill. USA). P-values below 0.05 were considered statistically significant.    
 
Results  
Figure 1 illustrates that the maternal age specific a priori risks derived from both software 
packages are similar. However, as is also demonstrated in Figure 1, risk estimates based on 
the combination of maternal age, biochemical findings and NT measurements were strikingly 
different. In fact, the combined risks derived from Wallac-Perkin-Elmer£software are in 
general lower than those derived from the FMF£software. This is especially true when the 
estimated risks are between 1 in 1000 and 1 in 100.000, thus not in the vicinity of any 
commonly used risk threshold value for invasive testing. To investigate the source of these 
differences, the contributions of the biochemical analyses and the NT measurements were 
investigated by calculating the likelihood ratios (LRs) with both software programmes.  
Figure 2 shows that the LRs based on the NT measurements using the Wallac-Perkin-
Elmer£software are significantly higher than the LRs derived from the FMF£software 
(p<0.001). Moreover, it is demonstrated that the FMF£ software truncates LRs based on NT 
at 0.12, a point where the Wallac-Perkin-Elmer£software gives higher LRs. In our study, the 
lowest LR based on NT as derived from the Wallac-Perkin-Elmer£software is 0.16. Figure 3 
shows that the LRs based on the biochemical parameters using Wallac-Perkin-
Elmer£software are statistically significantly lower than those derived on FMF£ software 
(p=0.01).  
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Figure 1 
 
 
Figure 1: Comparison of the a priori risks (∆) and the combined risks (○) derived from the FMF and Wallac-Perkin-
Elmer software packages (n=94). The solid line represents points of equal risk. The box illustrates a risk of 1 in 
250 (the threshold value for invasive testing). 
 
 
Figure 2 
 
 
Figure 2: Comparison of LRs based on NT measurements as calculated with the FMF and Wallac-Perkin-Elmer 
software packages (n=94). The solid line represents points of equal LRs. 
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Figure 3 
 
Figure 3: Comparison of LRs based on biochemical analysis of PAPP-A and fßhCG as calculated with the FMF 
and Wallac-Perkin-Elmer software packages (n=94). The FML truncates LRs based on NT at 0.12. The solid line 
represents points of equal LRs 
 
 
Figure 4 
 
Figure 4: Comparison of LRs based on the combined (i.e., multiplied) biochemical parameters and NT (n=94). 
Unlike the Wallac-Perkin-Elmer software, the FMF software applies an extra truncation at 0.1 for the multiplied 
LRs. The solid line represents points of equal LRs. 
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In fact, the FMF£software truncates LRs based on the biochemical parameters at 0.14. At 
this truncation point the Wallac-Perkin-Elmer£software shows considerably lower LRs values. 
In Figure 4 the LRs based on the combined (i.e., multiplied) biochemical serum markers and 
NT as derived from each software package are compared. Again, there are statistically 
significant differences between Wallac-Perkin-Elmer£software and FMF£software (p=0.003), 
whereby LRs derived from the Wallac-Perkin-Elmer£software are generally lower than those 
derived from The FMF£software. This may be due to an extra truncation at 0.1 for the 
multiplied LRs, as applied by the FMF£ software and not by the Wallac-Perkin-
Elmer£software.  
 
Discussion  
Much time is spent by caregivers on counselling women about their individual risk for trisomy 
21 as derived from non-invasive testing in the first trimester of pregnancy. Counsellors, 
thereby, typically rely on the reported numerical risk estimates. This information is 
communicated to their parents often in a sterile and ‘matter-of-fact’ way 12. Most caregivers 
and parents, however, have difficulty in appreciating the true magnitude of the woman’s risk 
of having a child with trisomy. Conflicting or poorly presented statistical information may 
cause erroneous communication of  risks, with serious consequences such as undue parental 
anxiety or unwarranted invasive procedures 5, 12-13. This is not restricted to the first trimester 
of pregnancy. Discordances in individual risk estimates were also observed in women 
screened for trisomy 21 by second trimester markers 14. Software designs, and its underlying 
algorithms, have a major impact on test performance in terms of sensitivity, specificity, 
positive and negative predictive values. Most centres, however, are unsure of what method 
for calculating risks of trisomy 21 is used in their computer software packages 15. As a result, 
information on the test performance is often lacking.  
This study shows that with the same screening parameters, marked disparities were 
observed between numerical risk estimates derived from the FMF software package and 
those derived from Wallac-Perkin-Elmer£software. These disparities are mainly explained by 
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the truncation limits. While the discussion on risk estimation methods is lively and ongoing 16-
19, none of the published truncation limits have been seriously challenged 20. Truncation limits 
on both the MoM-values and the combined LRs may cause considerable disparities in the 
reported risk estimates, especially when the screening parameters move into the tails of the 
distributions. Since truncation can have such an important influence on the risk calculation, 
the software companies should have a transparent policy regarding information on truncation 
limits and reasons for their application. The means and standard deviations of the screening 
parameters for the normal and trisomy 21 populations, the correlation coefficients between 
screening parameters and weight correction equations can also have a considerable effect 
on LRs and subsequent risk estimations. Currently, manufactures constantly update software 
packages without fully informing caregivers who are involved in prenatal counselling about 
the changes made in their new releases. This is also true for FMF£ and Wallac-Perkin-
Elmer£. Recently, both manufacturers issued updates of their first trimester software 
packages without providing clear information about underlying algorithms and subsequent 
test performance. Hence, both the consumer and the caregiver rely on the diligence of the 
software developers.  
As stated by Muller et al. 14, it is important that the different manufacturers provide detailed 
information about the test performance of their software packages, in terms of detection rates 
and false positive rates, preferably as a function of maternal age. For both psychological and 
legal reasons, caregivers should incorporate such information when counselling pregnant 
women who consider non-invasive testing for trisomy 21. From the public health point of 
view, non-invasive testing for trisomy 21 should be preferably done in a standardized way, 
thereby incorporating a set of parameters that have a proven track record in terms of 
detection rates and false positive rates, and then use that set exclusively, while 
simultaneously monitoring its performance. 
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Abstract  
Objective: to evaluate a 20% downward shift in the pregnancy-associated plasma protein A 
(PAPP-A) concentration on the test performance of first-trimester screening (FTS) for Down 
syndrome (DS) following a flaw in the production of PAPP-A kits on FTS for DS.  
Methods: a retrospective re-evaluation of PAPP-A in stored sera. Including criteria were a 
maternal-weight-corrected PAPP-A MoM value < 0.9 and a biochemical risk of DS > 1: 200 
at the time of testing. 
Results: Of the 3100 women, 473 (15%) fulfilled the inclusion criteria. After combining the 
biochemical risk based on the incorrect PAPP-A values with nuchal translucency findings, an 
increased risk for DS was initially found in 107 women [false positive rate (FPR): 3.1].  
Eighty-two (77%) out of 107 women opted for invasive testing. Following re-analysis of 
PAPP-A, the biochemical risk and the combined risk were statistically significantly different 
from the initial risk estimates (p< 0.001.). We noticed that 25 women (30%) had invasive 
testing while this was unjustified given the re-analysed PAPP-A. 
Conclusion: Erroneous PAPP-A kits resulted in an increase of the FPR by 1.2%. There 
were no reports of iatrogenic miscarriage. The occurrence of this problem reaffirms the 
importance of continuous monitoring of quality in FTS.  
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Introduction 
In January 2007 the national program for prenatal screening for Down Syndrome (DS) has 
been implemented in the Netherlands 1. For this purpose, the first-trimester combined 
screening (FTS) test was advocated. This test encompasses the assessment of two 
biochemical markers in maternal serum, i.e. free beta human chorionic gonadotropin (free β-
hCG)  and  pregnancy-associated plasma protein A (PAPP-A), and the sonographic 
assessment of the fetal nuchal translucency (NT). Combining these three markers, together 
with maternal age, 76-91 % of the pregnancies with trisomy 21 can be detected with a 3-7% 
false positive rate 2-5. ‘Screen positive’ is defined as an increased risk of DS at the time of 
testing (> 1:200) 6.  
The seven screening laboratories in the Netherlands participate in the UK National External 
Quality Assessment Service (UK-NEQAS Edinburgh, United Kingdom) first trimester 
combined test quality assurance scheme. During early April 2009 the UK-NEQAS reported a 
downward shift in concentrations of PAPP-A over the previous months (Figures 1 and 2). In 
the same period health care providers from two sonographic prenatal screening centres in 
the region expressed their concern about the increase in number of screen-positive findings 
following combined risk calculation they encountered in the last months.  
Our regional laboratory, Star Medical Diagnostic Centre (Star-MDC), could confirm the 
downward shift in concentrations with an increase in percentage of monthly positive findings 
(18.0% compared to 13.7% over 2008). The multiple of the median (MoM) in de study period 
was 0.85 as compared to 1.01 in 2008. Because of a 20% difference in concentration, a 
retrospective study was performed.  
In the present retrospective study, we report the impact of the downward shift of the PAPP-A 
concentration on the test performance of the FTS test. The use of the erroneous PAPP-A kits 
in the study period (December 2008-April 2009) resulted in lower MoM values for maternal 
weight-corrected PAPP-A and, subsequently, to an unduly increased risk of DS in the subset 
of women. In the Netherlands invasive diagnostic testing, that is chorionic villus sampling or 
amniocentesis, is typically offered following a ‘screen-positive’  test result of the FTS test 6. 
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Figure 1: PAPP-A  accuracy in the period 2008 – 2010
(UK-NEQAS international data of the Delfia Xpress)
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Invasive diagnostic testing, however, is associated with an increased risk of miscarriage 7-12. 
In this context, in the present study, the number of miscarriages as a result of (unjustified) 
invasive diagnostic testing was also analysed.     
    
Materials and Methods 
The study period was identified as the period from 26 November 2008 to 14 April 2009. 
During the present evaluation period, 3100 stored maternal serum samples were analysed 
by the laboratory of Star-MDC using the DELFIA Xpress® analyzer (PerkinElmer, Turku, 
Finland) in May and June 2009.  
The study group was defined on the basis of a biochemical risk of Down syndrome > 1: 200 
at the time of testing 6  and a maternal-weight-corrected PAPP-A MoM value < 0.9. Only first-
trimester sera that were included in this study group during the described evaluation period 
were re-analysed.  
 
Back-up procedure in case of a reagent recall 
In the Netherlands there are seven officially registered laboratories for first-trimester 
biochemical screening, including the laboratory of Star-MDC, which is responsible for the 
southwest region of the Netherlands. In case of a reagent recall, there is an adequate back-
up situation in the Netherlands. Half of the screening laboratories uses the AutoDELFIA® 
analyser (PerkinElmer, Turku, Finland), while the other half uses the DELFIA Xpress® 
analyzer (PerkinElmer, Turku, Finland) 13. No downward shift had been observed for the 
PAPP-A kits used on the AutoDELFIA® analyzer. The Research & Development department 
of PerkinElmer (Turku, Finland) released a new PAPP-A kits in the second half of April 2009.  
 
Re-analysis process 
The re-analysis of maternal serum samples of the study group were performed in 2 rounds: 
Firstly, between 14 and 28 of April 2009, the Dutch reference institute for first-trimester 
serum screening, Diagnostic Laboratory for Infectious Diseases and Perinatal Screening, 
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National Institute for Public Health and Environment (RIVM) re-analysed the concentrations 
of PAPP-A in the most recently (from 1 March to 14 April: <6 weeks old) stored maternal 
serum samples. Secondly, in May and June 2009 the Star-MDC laboratory re-analysed the 
samples from 26 November 2008 to 1 March 2009 with the new released and qualified 
PAPP-A kits.  
Recalculated MoM values for PAPP-A and the corrected biochemical risk-assessment 
(based on PAPP-A and original free β-hCG) were reported to the collaborating sonographic 
centres for prenatal screening. These centres were asked to recalculate the FTS risk of 
Down syndrome with the original findings of the NT and the corrected biochemical risk of DS.  
The quality of the re-calculation process was assessed on a daily and monthly basis by 
calculation of the medians of the MoM PAPP-A.  
 
Information process 
All women in the study period initially having an increased risk (>1:200) for DS based on a 
(probably falsely) increased biochemical risk were informed by regular mail about their re-
calculated combined risk by the sonographic screening centres. In close cooperation with 
Star-MDC, the Foundation for Prenatal Screening in the southwest of the Netherlands made 
two templates for letters of information (The Foundation for Prenatal Screening in the 
southwest of the Netherlands is the regional centre of quality assurance, evaluating and 
monitoring of the national prenatal screening program.). One letter was intended for women 
who had received an increased risk after the FTS test and who remained ‘screen positive’ 
after re-analysis and re-calculation. The other letter was intended for those who initially had 
an increased risk, but who became ‘screen negative’ (<1:200) after re-analysis and re-
calculation. In theory, the latter group could have had an unnecessary invasive procedure. 
Complementary and extensive counselling was offered to women in both groups. This plan of 
action was carried out by Star-MDC under supervision of the Foundation for Prenatal 
Screening in the southwest of the Netherlands, and in cooperation with the Division of 
63 
 
Obstetrics and Prenatal Medicine at the Department of Obstetrics and Gynaecology, and the 
board of directors of the Erasmus University Medical Center in Rotterdam. 
 
Statistical analysis 
The paired t-test was applied to test whether the characteristics of these two groups were 
from the same population. The biochemical variables expressed as MoM-values are 
presented as medians and ranges. Statistical analyses were performed using the SPSS 
statistical package for Windows release 15.1 (SPSS Inc. Chicago, IL). Statistical significance 
was defined as a p-value < 0.05. 
 
Results 
With the rejected lot numbers of PAPP-A kits, we found a downward shift in PAPP-A 
concentration of -21.5% [95% confidence interval (CI): -43.2% to 0.3%], while with adequate 
lot numbers of the PAPP-A kits, we found a downward shift in PAPP-A concentration of -
3.6% (95% CI: -4.9 to -1.8%). This shift was confirmed by the reported results of the UK-
NEQAS. Under normal conditions, the ratio of PAPP-A concentration reported by Star-MDC / 
RIVM was 0.93 ± 0.05, while in the evaluation period, December 2008 to April 2009, the ratio 
was 0.73 ± 0.04. 
In the study period 473 (15%) out of 3100 test results were identified for re-analysis, re-
calculation and evaluation (Figure 3). In this group 17 women did not have an NT 
measurement and thus did not have the complete FTS test. Nine women had a miscarriage 
before NT measurement and seven women declined the option of an NT measurement 
during the ultrasound investigation and the FTS test was not done. In one case NT 
measurement was not performed because a serious fetal anomaly (Siamese twins) was 
diagnosed. Hence, a total of 456 women were included in our study. The study population 
was mainly white, that is 85% Caucasian, 8% Asian and 7% Afro-Caribbean. Median 
maternal age was 35.4 years (range 21 to 45.5 years). Of the 456 included women having 
had an FTS test during the study period, 107 (FPR 3.1) had an increased risk of DS after
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combining biochemical screening findings with the findings of NT and maternal age. Eighty-
two (77%) out of 107 women opted for an invasive procedure, that is, chorionic villus 
sampling or amniocentesis. Apart from the 82 invasive procedures on the basis of the 
‘increased risk’ (>1:200)  after the FTS test, another 17 invasive procedures were done in 
this group for other reasons, such as advanced maternal age (> 36 years) and abnormal fetal 
sonographic findings. After the PAPP-A re-analysis and the risk re-calculation, statistically 
significant differences were found between the PAPP-A MoM values, biochemical risk and 
the corrected risk after the FTS test (Table 1). The group of the initially increased combined 
risk of DS (n = 107) (FPR 3.1) was reduced to 71 (FPR 1.9) women with an increased risk 
based on the corrected measurements. All chromosome abnormalities (n=18) were confined 
to the group that remained having an increased risk or had a sonographic detected fetal 
malformation.  With the re-calculated combined risk for DS, probably fewer women would 
have opted for an invasive procedure. So the effect of the erroneous PAPP-A shift was to 
increase the FPR by 1.2% (95% CI: 0.82 to 1.61) or 38% (95% CI: 28.1% to 48.4%) that is, 
an extra 12 women in every 1000 with an unaffected pregnancy were offered an invasive 
test. In the study period we did not encountered fetal loss due to an invasive procedure. 
 
Table 1. Results of the re-analysis and recalculation 
 
           Before reanalysis / 
recalculation  
After reanalysis /  
recalculation  
p value 
paired t-test  
  Median (min-max) 
             (P25-P75) 
Median (min-max) 
             (P25-P75) 
 
     
PAPP-A MoM  0.35 (0.04-0.90) 
        (0.28-0.60) 
0.57 (0.05-1.20) 
        (0.38-0.75) 
< 0.001* 
BC risk    1:    97  (5-200) 
        (50-140) 
173  (5-700) 
        (85-240) 
< 0.001* 
FTS risk  1:  541  (2-2401) 
        (227-831) 
982  (2-4448) 
        (373-1371) 
< 0.001* 
     
 
Study period: 26 November 2008 - 14 April 2009 
Study group: defined as PAPP-A < 0.9 MoM and biochemical screening risk of > 1:200 
PAPP-A: pregnancy-associated plasma protein A  
MoM: multiple of the median  
BC: Biochemical screening of maternal serum (free β-hCG and PAPP-A). 
NT: nuchal translucency. 
FTS: First-trimester combined screening test (BC and NT) 
* Statistically significant at the level p < 0.05. 
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Discussion 
In this article, we describe the impact on FTS performance of an approximately 20% 
downward shift in the PAPP-A concentrations due to the erroneously produced PAPP-A kits 
used for the FTS test for DS. We evaluated the potential clinical consequences of this 
impact. Low PAPP-A MoM values may result in more ‘screen-positive’ test results after FTS 
test. Such an increase in screen-positive test results was noticed by the prenatal screening 
centres and the UK-NEQAS reports were indicative for the quality assessment by the 
laboratory in detecting the down shift in PAPP-A concentration. Counteractive actions were 
taken by the laboratory in re-analysis of stored blood samples, which were identified with a 
PAPP-A concentration that derived 10% of the standard of 1.0 MoM and with a biochemical-
based risk that could influence the combined risk in a negative way.  The first round of re-
analysis was performed by the RIVM. The second round of reanalysis was carried out by the 
Star-MDC laboratory as soon as the production problem of adequate PAPP-A reagents was 
resolved by PerkinElmer. Three weeks after reporting the shift to the head office of 
PerkinElmer information about the new lot number was available. 
In May 2009, the quality assurance activities of PerkinElmer formally stated in a letter that 
the FPR was increased due to a level shift downward in the measurement of the PAPP-A 
concentration. PerkinElmer confirmed that this level shift was not observed in the Maternal 
Health Early Controls, which have been used with the PAPP-A reagent. 
During corrective and preventative action activities, PerkinElmer identified the PAPP-A 
concentrations to be 7 to 24% lower than normal, the shift being more pronounced at lower 
concentrations. The primary cause was identified to be the DX-coated wells and one lot of a 
raw material used in the coating process. As a consequence PerkinElmer has taken 
measures to prevent recurrence by intensified testing of the raw material before taking new 
lot numbers of PAPP-A kits into use, and continue to develop incoming inspection of the raw 
material. Since then, PerkinElmer uses additional controls to ensure that the PAPP-A kits 
currently released do not have this problem. After this incident, during five days, four times a 
day, a sample from a pool of high levels and from a pool of low levels of PAPP-A and free β-
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HCG were testedeven as the daily routine control samples (three levels). The results were 
compared with the results of the previous lot number that has been proven to be reliable. 
New reagent kit lots are tested in the laboratory first, using pools of both high and low level of 
PAPP-A and free β-HCG, before using them in screening. 
This study underscores that a substantial delay in the interpretation of the internal and 
external quality assessment data may have serious consequences for the women who have 
to decide whether they opt for an invasive test or not. Both laboratories and manufacturers 
do need to evaluate their own performance critically and take all possible measures to 
ensure that they are providing high-quality risk estimates based on maximum precision 14-15. 
Very important are the UK-NEQAS reports in this quality assessment. However, health care 
professionals in the field of prenatal screening of DS are still accountable for the 
implementation of the FTS. A frequent audit of the distribution of the biochemical markers 
free β-hCG and PAPP-A alongside with the distribution of NT is advocated. We conclude that 
the consequences of erroneous low PAPP-A and thereby an increased biochemical risk 
calculation were considerable in terms of an increase of 30% (25/82) in unjustified invasive 
diagnostic testing from the group who opted for this procedure based on an increased 
combined risk estimate. Of the total study group 5% (25/456) had an invasive procedure that 
was based on an incorrect increased combined risk estimate. Fortunately, this has not 
resulted in iatrogenic miscarriages. Although the estimated risk of miscarriage as a result of 
invasive diagnostic testing is small (0.3-1.0%) 7-12, this decision should be taken on basis of 
an adequate FTS test result. It is plausible that the risk among the samples that were not re-
assayed for PAPP-A (i.e. the original 3100 minus 473), might also have changed and hence 
also could have influenced the screen-positive rate and FPR, but this cannot be shown in our 
analysis. However, any effect of this is considered small. 
Despite the absence of negative side effects, the need for continuous and vigorous 
monitoring and verification of quality in FTS test is of paramount importance.  
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Part 2    
Ultrasound issues in first-trimester screening 
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Chapter 5 
Jugular lymphatic sacs in the first trimester of 
pregnancy: the prevalence and the potential value in 
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Abstract 
Objective: To investigate the prevalence of detectable jugular lymphatic sacs in a setting for 
first-trimester screening for Down syndrome, and to evaluate the influence of jugular 
lymphatic sacs on the screening performance for chromosomal abnormalities.  
Methods: A prospective single centre study (Erasmus University Medical Center, Rotterdam, 
The Netherlands) over a period of 1 year (January 2003 to February 2004). First-trimester 
nuchal translucency measurement was performed in a study population of 415 fetuses. 
Additionally, the transversal plane with the spine and mandible was visualized to verify the 
presents of jugular lymphatic sacs. The jugular lymphatic sacs were measured anterior-
posterior.  The association between nuchal translucency and jugular lymphatic sacs was 
tested statistically. 
Results: Follow up was completed in 406 cases (97.8%). Jugular lymphatic sacs could be 
visualized in 98 out of 415 (23.5 %). The nuchal translucency thickness and the mean of the 
left and right jugular lymphatic sac were significantly correlated. 
Conclusion:  The sonographic visualization of jugular lymphatic sacs significantly predicts 
chromosomal abnormalities, although nuchal translucency is a better predictor. Nuchal 
translucency and jugular lymphatic sacs are strongly correlated and therefore not applicable 
in a combination test.  
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Introduction 
First trimester measurement of the nuchal translucency (NT) with maternal blood sampling is 
standard antenatal care in the Netherlands. This screening strategy is a sensitive method for 
the identification of fetuses at risk of aneuploidy 1-2 and is associated with increased risk of 
genetic syndromes and fetal structural malformations 3-4. Although many theories have been 
put forward a common morphogenesis explaining the interrelationship between the complete 
spectrum of fetal malformations and enlarged nuchal translucency is still lacking. Previous 
studies demonstrated abnormal developed jugular lymphatic sacs (JLS) in combination with 
an enlarged NT 5-7. Since a disturbance in the lymph-angiogenesis precedes the 
development of an increased NT 6-7, it is hypothesized that JLS size could be an earlier and 
better predictor of chromosomal abnormalities.  
We conducted an observational study to investigate the prevalence of detectable JLS and to 
evaluate the test performance by adding this parameter to first-trimester screening (FTS). 
This study was integrated in a setting for FTS for Down syndrome (DS).  
 
Methods 
During a period of 13 months (January 9, 2003-February 26, 20040, an observational study 
was performed. All women with singleton pregnancies who attended the department of 
Obstetrics and Prenatal Medicine of the Erasmus University Medical Center for first-trimester 
screening were informed about the study. Patients were included in this study after giving 
oral informed consent. Ultrasound examinations of 415 fetuses were carried out between the 
11 and 14 weeks’ of gestation.  
Scans were performed on an ATL HDI-3000 ultrasound system (Advanced Technology 
Laboratories, Seattle, WA, USA) transvaginally, using a 7-MHz probe or abdominally using a 
5-MHz probe. Gestational age was derived on the basis of the first day of the last menstrual 
period (LMP) and confirmed by ultrasound assessment of fetal biometry. The ultrasound 
examinations were carried out following the strict methodological criteria set by the Fetal 
Medicine Foundation (FMF)® 8-9. An experienced and special trained FMF-certified 
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sonographer (PH) conducted all first-trimester ultrasound examinations. The NT was 
measured in the mid-sagittal section of the fetus as the maximum thickness of the 
subcutaneous translucency between the soft tissue overlaying the cervical spine and the 
skin.  The presence and size of the jugular lymphatic sacs were investigated in a transversal 
plane through the mandible and spinal cord and confirmed in sagittal and coronal planes, 
where feasible. Measurements of the anterior-posterior size of the JLS were performed in the 
transversal plane as shown in Figure 1. 
 
 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. transversal plane through the mandible (M) and spinal cord (Sp). 
Bilateral normal size jugular lymphatic sac (JLS). Measurement of JLS is donein a anterior-posterior 
direction. 
M 
Sp 
JLS 
JLS 
x 
x 
+ + 
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Digital recordings of the first-trimester screening and a transverse plane of the neck, 
including mandible and spine cord and the presence or absence of the jugular lymphatic 
sacs, were collected for further analysis. In all women, first-trimester screening with 
additional fetal biometry and visualization, measurement and documentation of jugular 
lymphatic sacs were completed within a time frame of 30 minutes. Invasive procedures, i.e., 
transabdominal chorionic villus sampling at 11-14 weeks’ gestation or amniocentesis at 15-
19 weeks’ gestation, were performed, where indicated. Follow-up was obtained by means of 
questionnaires, which were returned to us by the obstetrician or midwife supervising the 
delivery.  
 
Statistical analysis 
If JLS could not be visualized the size was set to zero. The nonparametric Kendall’s Tau-b 
test, that takes ties into account, was done to measure the association between NT and JLS 
size. In the subset where JLS size is larger than zero, the Pearson correlation coefficient 
between NT and the logarithm of JLS size was determined.  
Statistical significance was defined as a p-value < 0.05. In the study group the risk of 
chromosomal abnormalities was modelled using binary logistic regression. Statistically 
significant effects and interactions were identified by backward stepwise elimination using the 
likelihood ratio test. The probability criterion for stepwise entry was set to 0.05 and for 
removal from the equation to 0.1. The statistical analyses were performed using the SPSS® 
statistical package for Windows release 11.1 (SPSS Inc. Chicago, IL).  
 
Results  
In the study period, a total of 415 women with a viable singleton pregnancy were evaluated. 
Median maternal age in the total study population was 36 years (range 18 to 43 years). The 
study population was mainly white, i.e. 95% Caucasian, 1.2% Asian and 3.8% Afro-
American. As a result of various pleas and reminders, complete follow-up was obtained in 
406 women (study group). 
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 Table 1. Chromosomal abnormalities. 
 
   N gest.age  NT JLS left JLS right  Test NT Test JLS 
 
Trisomy 21  N=7 12+5  3.1 2.1 2.9  + + 
    12+1  4.5 1.4 1.7  + - 
    12+4  4.6 4.3 6.4  + + 
    13+0  4.8 1.9 2.4  + +  
    13+6  5.2 15.5 14.6  + + 
    13+2  5.7 0.0 0.0  + - 
    13+6  8.5 4.6 4.5  + + 
Trisomy 18  N=3 11+2  5.3 6.6 6.1  + + 
    12+3  6.0 3.4 2.8  + + 
    13+4  4.3 1.7 1.3  + - 
Trisomy 13  N=1 12+4  1.6 0.0 0.0  - - 
Monosomy X  N=1 11+0  9.2 12.9 9.1  + + 
47 XYY   N=1 12+2  2.0 1.9 1.7  - - 
 
 
 
 
Table 2. Adverse pregnancy outcome. 
 
   N gest.age  NT JLS left JLS right  Test NT Test JLS 
 
 
Early fetal loss (<20 wks) N=5 11+3  2.0 0.0 0.0  - - 
    13+5  1.0 0.0 0.0  - - 
  13+1  0.8 0.0 0.0  - - 
  13+6  1.0 0.0 0.0  - - 
 13+3  1.0 0.0 0.0  - -  
Intra uterine fetal death N=2 13+5٭   3.8 0.0 0.0  + - 
    13+6  1.9 0.0 0.0  - -  
Neonatal death  N=2 12+1  1.5 0.0 0.0  - - 
    13+5°   2.3 2.8 2.9  - +  
٭ Second pregnancy. First pregnancy hydrops fetalis, TOP at 19 wks. 
° complex cor vitium.    
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In the latter group 13 chromosomal abnormalities (3.2 %) were detected, while adverse 
pregnancy outcome (fetal loss, fetal death and neonatal death) was documented in nine 
other cases (2.2%), as summarized in Tables 1 & 2. 
NT was successfully examined in all fetuses. There were no differences between the groups 
with regard to maternal age, ethnicity and gestational age at examination. Median gestational 
age was 12 weeks 3 days (range, 11 wks 0 days-13 wks 6 days) and median CRL was 
61.7mm (range, 45-84mm). After excluding the chromosomal abnormalities and adverse 
pregnancy outcome a subset group of 384 (94.6%) women with an uncomplicated pregnancy 
were included for final analyses. 
In this subset the 95th percentile for NT size was 2.5 mm. Women were therefore considered 
‘test-positive’ if the NT size was above this level. The JLS were detectable in 23% (97/406) 
women of the study group. In the same subset of 384 uncomplicated pregnancies the 95th 
percentile for the mean left and right JLS size was 2.0 mm. Women were therefore 
considered ‘test-positive’ if the JLS size was above this level. Median size of detectable JLS 
size was 1.7 mm, with a range of 0.7 mm up to 15.5 mm. In Table 1 shows that in the group 
of chromosomal abnormalities, all seven fetuses with trisomy 21 tested positive for NT and 
5/7 for JLS. For trisomy 18, all fetuses also tested positive for NT and 2/3 for JLS. The fetus 
with monosomy X (Turner syndrome, TS) tested positive for both tests. Because of 
hypoplasia of the lymphatic system in fetuses with TS 10, it is questionable whether these 
should be included in our study. However, during the ultrasound investigation, the karyotype 
was not yet known to the investigator and the septated hygroma colli was identified as an 
enlarged NT accompanied with bilateral enlarged JLS. Although NT can identify about 80% 
of the fetuses with trisomy 13 in a normal first trimester screening program 11 in our study one 
fetus with Patau syndrome was tested negative by NT and JLS (Table 1.). On ultrasound, 
however, dextro cardia was observed, which classified the fetus as at increased risk of 
chromosomal abnormality. An abnormal karyotype of 47 XYY is not associated with enlarged 
NT and was tested negative by both NT and JLS. In the group of adverse pregnancy 
outcome (Table 2.) post mortem reports on the early fetal loss were not available. In the 
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study group of 406 fetuses a significant non-parametric correlation (Kendall’s Tau-b, 
R=0.129) was found between NT and JLS (p-value < 0.01). As shown in Figure 2, the subset 
of fetuses, in which the mean left and right JLS size was larger than zero (N=97), showed a 
strong correlation between NT and the logarithm of JLS. 
 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2   
. Correlation between NT and the mean JLS in the subset of the study group, where measured JLS size is larger 
than zero: * adverse pregnancy outcome     • uncomplicated pregnancy outcome      ° chromosomal abnormality 
 
                                           
The Pearson correlation coefficient found was 0.636 and the p-value was highly significant 
(p-value < 0.001). The binary regression results are shown in Table 3. In this study group, NT 
in combination with maternal age and JLS did not contribute to a statistically better prediction 
of chromosomal abnormalities than NT alone. Moreover, as enlarged NT and JLS are 
strongly interrelated, these parameters cannot be considered independent and therefore not 
applicable in a multiple parameter binary logistic regression analysis. Although both NT and 
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JLS parameters are statistically significant predictors, the sensitivity for NT was better than 
for JLS.   
 
 
Table 3. Binary logistic regression results for chromosomal abnormalities 
 
  
Threshold 
(mm) 
 
 
Sensitivity 
(%) 
 
Specificity 
(%) 
 
Odds ratio 
 
95% confidence 
interval 
 
JLS 
 
 
2.0 
 
62 
 
95 
 
3.81° 
 
2.19 
 
6.64 
 
NT 
 
2.5 
 
85 
 
95 
 
5.53° 
 
3.12 
 
9.82 
 
 
 
Women were considered screened positive if the distance was above this level. 
°Statistically significant at the level P<0.001. 
  
Discussion  
This study was carried out to evaluate the prevalence of JLS and was integrated in a setting 
of FTS for DS to evaluate its test performance in the screening for chromosomal 
abnormalities. The association between NT, JLS and fetal outcome were investigated. In this 
context, the prerequisite for adding JLS to first trimester measurement of the nuchal 
translucency is its independent association with chromosomal abnormalities. 
Nuchal translucency is a subcutaneous fluid accumulation in the neck region of unknown 
origin. However, Haak et al. 7, 12 showed that in mouse embryos with trisomy 16 the 
development of the JLS preceded the NT and that the JLS showed distension just prior to the 
occurrence of the increased NT. This notion was supported by other investigators 5-6, 13-14. 
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Trisomy 16 mouse embryos are considered to be the animal model of the trisomy 21 in 
human fetuses 15-18. The delayed organization and connection of these JLS to the venous 
circulation might explain the transient nature of the NT. Human studies on NT and JLS 5, 7, 12-
14, 19 were not able to give conclusive evidence on the question if JLS precedes NT or visa 
versa. It merely suggests that there seems to be a fetus-specific pattern in the development 
of the jugular lymphatic system, and therefore a unique expanding phase of the jugular 
lymphatic sacs.  
If the development of JLS in human fetuses is similar to the animal model of the T 16 mouse 
embryo 5-7, 12-14, further analysis might determine its possibility as an early marker for 
chromosomal abnormalities before the 11th week of gestation. Considering the large number 
of attrition of chromosomal abnormal pregnancies and pregnancies with major anomalies 
during the first trimester, this additional value is still to be discussed. The absence of JLS in 
early pregnancy could perhaps be used as a sonographic marker for ruling out chromosomal 
abnormalities (negative predictive value). In our study, the smallest  
JLS size detectable by ultrasound was 0.7 mm, which approximated the spatial resolution of 
the ultrasound equipment in combination with the 7 MHz transvaginal and 5 MHz 
(broadband) abdominal transducers. In fact, the ability to detect JLS is limited by the spatial 
resolution of ultrasound machines.  Although one could hypothesize that improvement of 
ultrasound imaging performance might improve the visualization of small JLS, their potential 
additional value for the early detection of fetal chromosomal abnormalities merits further 
scientific research. Nevertheless, the sonographic visualization of JLS smaller than.2, 0 mm 
is time consuming and requires specially trained and highly skilled ultrasound operators.  
From our study, we conclude that clearly visualized JLS significantly predict chromosomal 
abnormalities, although NT is a better predictor. In terms of test performance, however, the 
additional value of combined testing is limited as both predictors are interrelated.  
83 
 
References  
 
1. Snijders, RJ, Sebire, NJ, Nayar, R, Souka, A, Nicolaides, KH. Increased nuchal translucency 
in trisomy 13 fetuses at 10-14 weeks of gestation. Am J Med Genet 1999;86:205-7. 
2. Zoppi, MA, Ibba, RM, Putzolu, M, Floris, M, Monni, G. Assessment of risk for chromosomal 
abnormalities at 10-14 weeks of gestation by nuchal translucency and maternal age in 5,210 fetuses 
at a single centre. Fetal Diagn Ther 2000;15(3):170-3. 
3. Souka, AP, Snijders, RJ, Novakov, A, Soares, W, Nicolaides, KH. Defects and syndromes in 
chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of 
gestation. Ultrasound Obstet Gynaecol 1998;11:391-400. 
4. Souka, AP, Von Kaisenberg, CS, Hyett, JA, Sonek,JD, Nicolaides, KH. Increased nuchal 
translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-21. 
5. Bekker, MN. From lympatic development to nuchal translucency. Amsterdam: VU Medical 
Center; 2007. 
6. Gittenberger-de Groot, AC, van den Akker, NM, Bartelings, MM, Webb, S, van Vugt, JM, 
Haak, MC. Abnormal lymphatic development in trisomy 16 mouse embryos precedes nuchal edema. 
Dev Dyn 2004;230:378-84. 
7. Haak, MC, Bartelings, MM, Jackson, DG, Webb, S, van Vugt, JM, Gittenerger-de Groot, AC. 
Increased nuchal translucency is associated with jugular lymphatic distension. Hum Reprod 
2002;17:1086-92. 
8. Pandya, PP, Snijders, RJ, Johnson, SP, De Lourdes Brizot, M, Nicolaides, KH. Screening for 
fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. 
Br J Obstet Gynaecol 1995;102 (12):957-62. 
9. Snijders, RJ, Noble, P, Sebire, N, Souka, A, Nicolaides, KH. UK multicentre project on 
assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 
weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 
1998;352(9125):343-6. 
10. von Kaisenberg, CS, Nicolaides KH, Brand-Saberi, B. Lymphatic vessel hypoplasia in fetuses 
with Turner syndrome. Hum Reprod 1999;14:823-6. 
84 
 
11. Snijders, RJ, Sebire, NJ, Nayar, R, Souka, A, Nicolaides, KH. Increased nuchal translucency 
in trisomy 13 fetuses at 10-14 weeks of gestation. Am J Med Genet 1999;86:205-7. 
12. Haak, MC. Nuchal translucency and cardiac failure. Amsterdam: VU Medical Center; 2003. 
13. Bekker, MN, Haak, MC, Rekoert-Hollander, M, Twisk, J, van Vugt, JM. Increased nuchal 
translucency and distended jugular lymphatic sacs on first-trimester ultrasound. Ultrasound Obstet 
Gynaecol 2005;25:239-45. 
14. Bekker, MN, van den Akker, NM, Bartelings, MM, Arkesteijn, JB, Fischer, SG, Polman, JA, 
Haak, MC, Webb, S, Poelman, RE, van Vugt, JM, Gittenberger-de Groot, AC. Nuchal edema and 
venous-lymphatic phenotype disurbance in human fetuses and mouse embryos with aneuploidy. J 
Soc Gynecol Investig 2006;13:209-16. 
15. Holtzman, DM, Bayney, RM, Li, YW, Khosrovi, H, Berger, CN, Epstein, CJ, Moblev, WC. 
Dysregulation of gene expression in mouse trisomy 16, an animal model of Down syndrome. Embo J 
1992;11:619-27. 
16. Miyabara, S, Gropp, A, Winking, H. Trisomy 16 in the mouse fetus associated with generalized 
edema and cardiovascular and urinary tract anomalies. Teratology 1982;25:369-80. 
17. Reeves, RH, Irving, NG, Moran, TH, Wohn, A, Kitt, C, Siscodia, SS, Schmidt, C, Bronson, RT, 
Davisson, MT. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 
1995;11:177-84. 
18. Von Kaisenberg, CS, Krenn, V, Ludwig, M, Nicolaides, KH, Brand-Saberi, B. Morphological 
classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a 
trisomy 16 mouse. Anat Enbryol (Berl) 1998;197:105-24. 
19. Bekker, MN, Twisk, JW, Bartelings, MM, Gittenberger-de Groot, AC, van Vugt, JM. Temperal 
relationship between increased nuchal translucency and enlarged jugular lymphatic sac. Obstet 
Gynecol 2006;108:846-53. 
 
 
 
85 
 
Chapter 6 
Second-tier risk assessment after first-trimester 
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risk 
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Abstract 
Objectives: To evaluate the additional value of specific sonographic markers to further 
assess the risk of trisomy 21, 18 and 13 in women with an intermediate increased risk of 
trisomy 21, 18 and/or 13 after the first-trimester combined test.  
Methods: During a 30 months period the combined test (CT) ‘plus’ was evaluated among 
women at intermediate risk (i.e., > 1: 200 and < 1: 50).  The CT-plus was based on the 
assessment of sonographic makers, including the nasal bone, the Doppler velocity waveform 
of the ductus venosus, tricuspid regurgitation and the fronto-maxillary facial angle.   
Results: In 190 women the CT-plus was performed. A low sensitivity (0.25; 95% CI: 0.01 – 
0.78) and high specificity (0.80; 95% CI: 0.73 – 0.85) were found, resulting in a decrease of 
the false positive rate coinciding with a decrease in the detection rate of fetal aneuploidy. 
Conclusions:  The CT-plus is a tool that can be used for decreasing the false-positive rate 
after the first-trimester combined test. Decrease in screen-positive rates leads to fewer 
invasive procedures and, subsequently, prevents potential iatrogenic miscarriages. However, 
the assessment of specific sonomarkers among this specific category of women at 
intermediate risk of trisomy 21 and 18 is of limited value, since a relatively large proportion of 
fetal aneuploidy will be missed.  
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Introduction 
Since January 2007 in the Netherlands the first trimester combined test has officially been 
introduced as a screening test for the detection of trisomy 21. In June 2010 this test has 
been extended to the detection of trisomy 13 and 18. This test is offered to every pregnant 
woman in the first trimester of pregnancy. First-trimester screening (FTS) by the combined 
test provides an individual risk estimation, based on the combination of maternal age, fetal 
nuchal translucency (NT) and two biochemical markers in maternal blood, i.e., free ß-human 
chorionic gonadotropin (ß -hCG) and pregnancy-associated plasma protein-A (PAPP-A). By 
combining these markers 76-91 % of the pregnancies with trisomy 21 can be detected with a 
3-7% false positive rate 1-5.  
Women are considered ’screen positive’ when the test result indicates an increased risk of 
trisomy 21, 18 and/or 13, i.e. a risk of ≥ 1:200. To these women an invasive diagnostic test 
such as chorionic villus biopsy or amniocentesis is offered. Some of them, however, are 
reluctant to have invasive testing because these tests are associated with a risk of iatrogenic 
miscarriage (0.3-0.5%) 6-11. Additional sonographic markers have been identified to assess 
the risk of trisomy 21, 18 and 13 in the first trimester of pregnancy. These markers include 
the nasal bone (sensitivity 60-70%, specificity 98%)12,13, fronto-maxillary facial angle 14, 
ductus venosus (sensitivity 80%, specificity 95%)15, and tricuspid valve Doppler evaluation 
(sensitivity 70% and specificity 95%)16. This approach, the so-called combined test ‘plus’ 
(CT-plus) has been used as a second-tier test following FTS. It is hypothesized that CT-plus 
may achieve higher detection rates than screening by the combined test alone (detection 
rate by using two markers 94%, three markers 95%, and four markers 96%) and a decrease 
in false positive test results (false positive rate of 2% for trisomy 21 17. A decrease in 
iatrogenic miscarriages due to invasive procedures can be expected if less invasive 
procedures are performed.   
In this study we evaluate the additional value of CT-plus examination in women with an 
intermediate risk of trisomy 21, 18 and/or 13 after the first trimester combined test with 
respect to outcomes (karyotyping) and number of invasive procedures after the CT-plus.
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Methods  
From July 2010 to December 2012 CT-plus was performed among all eligible women with 
singleton pregnancies who were referred to the department of Obstetrics and Prenatal 
Medicine of the Erasmus University Medical Center, Rotterdam, The Netherlands. Women 
were potentially eligible if they tested ‘screen positive’ for trisomy 21, 18 and/or 13 after the 
first-trimester combined screening test (NT, maternal age and serum markers). ‘Screen 
positive’ was defined as an increased risk at the time of testing of ≥ 1 in 200 18. In case of a 
NT ≥ 3.5mm or a risk greater than 1 in 50, women were excluded and only an invasive test 
was offered.  Hence, women at intermediate risk (i.e., ≥ 1 in 200 and ≤ 1 in 50) were 
counselled about the options for subsequent testing, i.e., sonographic assessment of 4 
markers to recalculate the risk of trisomy 21, 18 and 13 (the so-called CT-plus approach), 
and/or invasive testing or wait and see. The use of the CT-plus test was always counselled 
as being assessed in a clinical trial. Regardless of the result of the CT-plus test, the option of 
invasive testing was always available. In case of an abnormal marker women were offered 
an advanced fetal anomaly scan at 20 weeks of gestation.  
The CT-plus ultrasound examinations were performed following the strict methodological 
criteria set by the Fetal Medicine Foundation (FMF®). The presence or absence of the nasal 
bone, the Doppler velocity waveform of the ductus venosus, tricuspid regurgitation and the 
fronto-maxillary facial angle were evaluated additional to the NT. All ultrasound examinations 
were conducted by four FMF-certified sonographers (PH, KH, EG and AR).  Scans were 
performed on a GE Voluson E8 system (GE, Zipf, Austria) either transvaginally, using a 5-9 
MHz probe or abdominally using a 2-7 MHz probe.  
The maternal serum samples were analysed with the AutoDELFIA analyser (Perkin Elmer 
Life Science, Boston, MA, USA) and commercially available kits. Analysis was carried out at 
the laboratory of Star Medical Diagnostic Center in Rotterdam, one of the six regional 
laboratories for FTS in the Netherlands. The calculations of the maternal-weight-corrected 
Multiple of the Mean (MoM) of the biochemical markers were done using the LifeCycle-Elips 
software (PerkinElmer Life Science, Boston, MA, USA). For the final CT-plus risk estimation, 
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the ultrasound data and the results of the maternal serum analysis of the free β-hCG and 
PAPP-A were combined in the FMF-module in an obstetrical software database (Astraia®, 
version 1.21.7, Astraia Software GmbH, München, Germany). 
Follow-up was obtained by means of questionnaires, which were returned to us by the 
obstetrician or midwife supervising the delivery. The sensitivity (detection rate) was 
calculated by dividing the number of true positives by the number of true positives plus the 
number of false negatives. The specificity (true negative rate) was calculated by dividing the 
number of true negatives by the number of true negatives plus the number of false positives.   
 
 
Table 1: Study group characteristics (N = 190) 
Parameter  Median Range 
Maternal age (years) 35 22 – 44 
Risk trisomy 21 CT 1:130 1 :52 – 1:4471 
Risk trisomy 18 CT 1:2646 1:53 – 1:72334 
Risk trisomy 13 CT 1:2590 1:108 – 1:126128 
β-hCG (MoM) 1.46 0.22 – 10.66 
PAPP-A (MoM) 0.43 0.09 – 2.55 
NT (mm) 1.8 1.1 – 3.5 
Risk trisomy 21 CT-plus 1:1398 1:2 – 1:19206 
Risk trisomy 18 CT-plus 1:6579 1:6 – 1:50302 
Risk trisomy 13 CT-plus 1:13746 1:15 – 1:157443 
GA at birth (weeks) 39 3/7 14 6/7 – 41 6/7 
Birth weight (gram) 3350 135 – 4755 
CT = first trimester combined test. MoM = Multiple of the Mean. NT = Nuchal translucency.   
CT-plus = Combined test plus. GA = gestational age.   
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Results 
In the 30 months period 191 women at intermediate risk were included in the study. One 
woman was excluded due to maternal obesity and unfavourable position of the fetus. In this 
woman a chorionic villi biopsy was performed, showing normal karyogram. Baseline 
characteristics and neonatal outcome are shown in Table 1. In three women the risk of 
trisomy 13 and 18 was not calculated in the first trimester combined test. In 9 women the GA 
at time of birth was unknown, and in 12 women information of birth weight was missing.   
 
Figure 1: Flowchart showing the results and outcome after CT-plus test.  
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In 160 women there was an intermediate risk of trisomy 21 based on the first trimester 
combined test. 16 women had an intermediate risk of trisomy 18 and one had an 
intermediate risk of trisomy 13. In 13 women, an intermediate risk existed for more than one 
aneuploidy. Seven women had an intermediate risk of both trisomy 21 and trisomy 18, while 
one woman had an increased risk of trisomy 18 and 13, two women of trisomy 21 and 13. 
Three women had an intermediate risk of trisomy 21, 18 as well as trisomy 13.    
After CT-plus 39 (21%) out of the 190 women remained at increased risk of trisomy 21, 18 
and/or 13. Of these 39 women 24 chose invasive testing while 15 women decided to wait 
and see. Of the 151 women at low risk after CT-plus 14 women chose invasive testing and 
137 opted for wait and see (Figure 1).  
In three women CT-plus gave a false negative result. In two of them CT-plus showed a low 
risk of trisomy 21 (1 in 5861 and 1 in 3460); in one of these two women the fronto-maxillary 
facial angle could not be measured, all other markers were normal. Post-partum the both 
neonates were diagnosed with trisomy 21. In the third woman CT-plus showed a low risk of 
trisomy 21, as well as 18 and 13 (1:352 vs 1:647 vs 1:2951), all markers were normal. At the 
20-weeks’ fetal anomaly scan multiple congenital anomalies were seen; trisomy 18 was 
diagnosed by subsequent amniocentesis.  
The detection and false positive rates of the CT-plus are shown in Table 2. In 38 women the 
CT-plus gave a false positive result, meaning the CT-plus indicated an increased risk while 
the child was born without a trisomy 21, 18 or 13. In one woman there was a true positive 
result, the CT-plus showed an increased risk of trisomy 21 (1 in 3) and trisomy 21 was 
diagnosed by chorionic villus biopsy. The odds of being affected given a positive result 
(affected positive: unaffected positive) was found to be 1 in 38.   
In 148 women the test gave a true negative result, meaning the CT-plus indicated a low risk 
and the child was born without trisomy 21, 18 or 13. In this study there were 10 unexpected 
findings. In one woman who had an increased risk after CT-plus examination, was diagnosed 
with trisomy 20 mosaicism by amniocentesis. The other unexpected findings included an 
unbalanced translocation of chromosome 6; 16, two intra-uterine fetal deaths, a right 
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diaphragmatic hernia, hypospadias, hydrocephalus, arachnoid cyst, a skeletal dysplasia and 
hypoplastic right heart syndrome. Only in the trisomy 20 mosaicism an abnormal Doppler 
velocity waveform of the ductus venosus was found; all other markers were normal in the 
group with unexpected findings. The characteristics of these women are shown in Table 3.  
 
 
Table 2: evaluation of the CT-plus for detection of trisomy 21, 18 and 13.  
 Trisomy 21, 18 or 13  No trisomy 21, 18 or 13 Total 
CT-plus Positive 1 38 39 
CT-plus Negative 3 148 151 
Total 4 186 190 
  95% CI  
Sensitivity 0.25 0.01 – 0.78  
Specificity 0.80 0.73 – 0.85  
CI = Confidence Interval 
     
 
Discussion 
In this study we evaluated the additional value of specific sonographic markers to assess the 
risks of trisomy 21, 18 and 13 in women who were at intermediate risk of these chromosomal 
abnormalities after the first trimester combined test. We found a low sensitivity and high 
specificity, resulting in a relatively low false positive rate which coincides with a low detection 
rate of fetal aneuploidy. 
FTS is widely used and acknowledged as valuable screening test for fetal aneuploidy. 
Women who tested ‘screen positive’ are reluctant to have subsequent invasive testing 
because of the risk of iatrogenic miscarriage. For that reason, further non-invasive 
assessment of the fetus is of interest since this may reduce the false positive rate following 
FTS. The added value of the additional first trimester ultrasound markers was summarised in 
a review by Sonak and Nicolaïdes 17 who concluded that the addition of the sonomarkers for 
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aneuploidy increases the detection rate for Down syndrome while decreasing the false-
positive rate. The authors, however, had a different definition of ‘intermediate’ risk. Their 
definition represented a risk of 1 in 51 to 1 in 999. This will increase the burden of the 
ultrasound department as women who are considered low risk after FTS (< one in 200) will 
be advised to have further sonographic testing. Moreover, this will create more anxiety 
among the pregnant women involved. Recently, Ghaffari et al. 19 conducted a prospective 
study among 13.476 women in Tehran who were screened for chromosomal abnormalities in 
the first trimester of pregnancy. They followed the ALARA (as low as reasonably achievable) 
principle, where nasal bone status, tricuspid valve regurgitation and ductus venosus Doppler 
flow were measured, where feasible. In 34.4% they succeeded to assess these additional 
sonomarkers, with subsequent increase in detection rates for trisomy 21 and decrease of 
false-positive rates at a cut-off level of < 1 in 300 for subsequent invasive testing.  Such 
approach, however, is time consuming and requires high-skilled sonographers.  For this 
reason, this approach does not seem appropriate in a screening setting.  
Although the FTS is primarily and most effectively used for trisomy 21 screening, a positive 
side effect is the early identification of fetus with trisomy 18 or trisomy 13, which are the 
second and third most frequent chromosomal abnormalities. Kagan et al. concluded that ~ 
95% of trisomy 18 and 13 fetus can be detected with a 0.1 % increase in the false positive 
rate 20. A large proportion (38%) of the women having an increased risk following CT-plus did 
not change their mind about invasive testing since they did not opt for invasive testing 
despite their increased risk of trisomy 21, 18 or 13. Especially with the recent introduction of 
the non-invasive prenatal diagnosis 21,22 of trisomy 21, 18 and 13 the question arises which 
role remains the ultrasound in the follow-up assessment of those who screen positive after 
FTS. It is known that an abnormal flow in the ductus venosus, an abnormal flow over the 
tricuspid valve and an increased NT thickness are associated with cardiac defects 23-29, and 
that the majority of significant structural defects are already detectable at this point in 
pregnancy 17,30. It is likely that in the near future the first trimester scan becomes a fetal 
anomaly scan rather than a screening tool for aneuploidy. In this study we found ten 
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unexpected findings indicating that pregnancies with an increased risk of aneuploidy are also 
at risk for other congenital anomalies, this should be kept in mind when monitoring these 
pregnancies. We conclude that the CT-plus is a tool that can be used for decreasing the 
false-positive rate after the FTS. The decrease in screen-positive rates leads to fewer 
invasive procedures and in that way prevents iatrogenic miscarriages. However, among this 
specific category of women at intermediate risk examination of specific sonomarkers missed 
3 out of 4 fetuses with fetal aneuploidy. 
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 Abstract 
Objectives: To examine whether embryonic volume (EV), as measured using three-
dimensional (3D) ultrasound and a virtual reality approach, is a better measure of growth 
restriction than is crown-rump length (CRL) in aneuploid fetuses.  
Methods: We retrospectively measured CRL and EV in prospectively collected 3D 
ultrasound volumes of 55 aneuploid fetuses using the Barco I-Space VR system. The 
gestational age ranged from 11+2 to 14+4 weeks. We compared our measured data with 
previous published reference curves of euploid fetuses. Delta-values were calculated by 
subtracting the expected mean of euploid fetuses of the same gestational age from observed 
values. The one-sample t-test was used to test significance of differences observed. 
Results: The CRL measurements of fetuses with trisomy 21 (n=26), trisomy 13 (n=5) and 
monosomy X (n=5) were comparable with those of euploid fetuses, but in fetuses with 
trisomy 18 (n=19) the CRL was on average 14.5% smaller (p<0.001). The EV in fetuses with 
trisomy 21, 18, 13 and monosomy X was smaller than euploid fetuses (-27.8%, p<0.001; -
39.4% p=<0.001; -40.9%, p=0,004 and -27.3% p=0.055, respectively). 
Conclusion: When relying on CRL measurements alone, first-trimester growth restriction 
especially manifest in trisomy 18. Using EV, growth restriction is also evident in trisomy 21, 
13 and monosomy X. EV seems to be an effective measurement for assessment of first-
trimester growth restriction in aneuploid fetuses. 
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Introduction 
It has been known for a long time that fetal growth restriction may be a marker for aneuploidy 
1-3. Typically, growth restriction in aneuploid pregnancies is of early onset, and is evident from 
the first trimester onwards. In trisomy 21, however, crown-rump length (CRL) measurements 
are similar to chromosomally normal fetuses of the same gestational age (GA) 1, 3. 
Traditionally, first trimester fetal growth has been documented by two-dimensional (2D) CRL 
measurements. With the introduction of three-dimensional (3D) ultrasound (US) it became 
possible to measure embryonic and fetal volumes. Earlier studies show that the relative 
increment of fetal volume is much larger than the increment of CRL during the same period 4. 
Rousian et al.4 demonstrated that, when the CRL doubles, the embryonic volume (EV) 
increases 6.5-fold. Volume measurement might therefore enable earlier detection of fetal 
growth restriction in pregnancy. 
Several other studies have been performed measuring fetal volumes using 3D US 5-8. To 
estimate the embryonic or fetal volume in these studies 2D contours were defined manually 
in several different planes. As various methods have been used and different normal values 
for EV have been reported there is a need for standardization 9-10. 
The introduction of the virtual reality (VR) visualization technique enables us to use all three 
dimensions of these 3D US scans. The Erasmus MC operates a BARCO I-Space VR system 
(Barco NV, Kortrijk, Belgium). This is a four-walled CAVETM -like VR system in which 
investigators are surrounded by stereoscopic images 11. A hologram is created by the V-
Scope volume rendering application and polarized glasses enable the viewer to perceive 
depth and to interact with 3D volumes in an intuitive manner 12. Using V-Scope it is possible 
to perform precise EV calculations semi-automatically while benefitting from true 3D depth 
perception 4.  
The aim of this study was to examine fetal growth pattern in aneuploid fetuses (trisomy 21, 
18, 13 and monosomy X) during the late first trimester and to compare EV and CRL between 
euploid and aneuploid pregnancies.  
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Methods 
Between 2008 and 2010 we collected 3D ultrasound volumes of singleton pregnancies in 
which an increased nuchal translucency (NT) was measured (>3.5 mm) during routine 
ultrasound examination. Ultrasound scans were performed using the Voluson 730 Expert 
ultrasound machine (GE Medical Systems, Zipf, Austria). Later, following invasive prenatal 
diagnosis, aneuploid pregnancies were identified (N=63). The GA was calculated based on 
the first day of the last menstrual period or, when assisted reproductive technology had been 
carried out, on the day of conception; GA ranged from 11+2 to 14+4 weeks. 
The 3D volumes were converted to Cartesian volumes, using 3D software (4D View, GE 
Medical Systems), and transferred to the BARCO I-Space. In the I-Space all volumes were 
evaluated and the best volume for each case was selected based on image quality and 
completeness of the volume. We excluded eight cases from the study because of poor image 
quality (n=5), incompleteness of the volume (n=1) or because of absence of fetal heart 
activity at the time of ultrasound scan (n=2). Of these eight cases three were diagnosed with 
trisomy 21, three with trisomy 18 and two with monosomy X (45, XO). There were four 3D 
volumes (two cases with trisomy 21 and two cases with trisomy 18) in which it was not 
possible to measure EV because of poor image quality, but in which it was possible to 
measure CRL. Following exclusions, 26 pregnancies trisomy 21, 19 with trisomy 18, five with 
trisomy 13 and five with monosomy X were available for analysis. A fetus affected with 
trisomy 18 as visualized in the I-Space VR-system is shown in Figure 1. 
CRL and EV were measured using the V-Scope software. The V-Scope application includes 
a region-growing segmentation algorithm for semi-automatic volume calculation in selected 
structures 11-12. The innovative VR technique has already successfully been applied in 
prenatal medicine 13-15. 
The procedure for measuring EV is described in detail by Rousian et al.4 Both physiological 
and pathological omphalocele were included in the embryonic volume. Hydrops, frequently 
present in fetuses with chromosomal abnormalities, was also included in the embryonic 
volume calculations. This is relatively easy to archive y performing a second segmentation of 
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the anechonic fluid layer of the hydrops, aside from the segmentation of the body volume. If 
necessary this fluid layer can also be segmented manually. All measurements in the I-Space 
were performed by the same investigator (LB). The accuracy and reproducibility of length 
and volume measurements has been proven by previous studies in which the growth 
trajectories of euploid pregnancies for CRL and EV have also been determined and 
reference curves established 4, 16-18. The collected data in the present study were compared 
to the results of these previous studies on euploid fetuses. 
 
Figure 1. 
                                               
Figure 1: Fetus affected by trisomy 18 as visualized in the I-Space 
 virtual reality system. Multiple congenital abnormalities can be seen:  
Exencephaly, radial aplasia and omphalocele. Spina bifida and  
polydactyly were also present. 
 
 
Statistical analysis 
The expected mean EV of the euploid fetuses at the same GA was subtracted from the 
observed EV of aneuploid fetuses. This expected value was obtained from equations 
published in earlier studies 4, 17-18, and the difference was expressed as a proportion of the 
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mean EV of euploid fetuses. The same analysis was performed to investigate the possible 
association of EV and CRL, and for CRL and GA. We furthermore determined the difference 
in GA, comparing observed GA and expected GA (expressed in days) according to the 
observed EV and CRL. The one-sample t-test was used to test for statistically significant 
differences between observed values of aneuploid pregnancies and expected values of 
euploid pregnancies. Statistical analysis was performed using SPSS v.17.0.2 (SPSS Inc., 
Chicago, IL, USA) and p-value <0.05 was considered statistically significant. 
 
Results 
Of the 26 trisomy 21 cases three presented with hydrops and/or hygroma colli. In the trisomy 
18 group nine were diagnosed with a pathological omphalocele and four with hydrops fetalis. 
Three of the 19 trisomy 18 cases had multiple congenital malformations (exencephaly, 
holoprosencephaly, spina bifida, skeletal abnormalities, and nephron-urinary abnormalities). 
Two cases of holoprosencephaly, three cases with hydrops and/or hygroma colli, one 
omphalocele and one hypoplastic left heart syndrome were diagnosed in the trisomy 13 
group. Three of the five cases with monosomy X presented with hydrops. Other congenital 
abnormalities diagnosed in this group were hydronephrosis and cardiac abnormalities. 
Fetuses diagnosed with trisomy 18 showed a 14.53% smaller CRL than expected (p<0.001), 
corresponding to a differences in GA of -4.78 days. The other groups of aneuploid fetuses, 
trisomy 21 and 13 and monosomy X, showed a non-significant smaller CRL than did euploid 
fetuses (Table 1).  
In all groups o aneuploid fetuses the EV was smaller than expected for gestational age: -
27.76% for trisomy 21 (p<0.001), -39.37% for trisomy 18 (p<0.001), -40.87% for trisomy 13 
p=0.004, although the difference was not quite statistically for monosomy X (-27.29%, 
p=0.055). In terms of days’ GA, these differences ranged from -3.45 to -5.14. 
In Figure 2, the CRL and EV of fetuses with trisomy 21, 18 and 13 and monosomy X are 
plotted gestational-age based reference ranges for euploid fetuses. 
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Table 1: Mean percentage difference in crown-rump length and embryonic volume in aneuploid fetuses as a 
percentage of normal mean according to gestational age (GA) in euploid fetuses, with corresponding mean 
differences in GA. 
Karyotype n Mean difference % 
(95% CI for mean) 
p* Mean difference 
days GA (SD)  
p* 
Crown-rump length 
Trisomy 21 
 
26 
 
-1.29 (-4.97 to 2.38) 
 
0.475 
 
-0.55 (-1.79 to 0.69) 
 
0.369 
Trisomy 18 19  -14.53 (-19.94 to -9.12) <0.001 -4.78 (-6.77 to -2.78) <0.001 
Trisomy 13 5 -5.44 (-14.39 to 3.52) 0.167 -1.75 (-4.55 to 1.06) 0.159 
Monosomy X 5 -3.65 (-18.72 to 11.43) 0.539 -1.43 (-6.18 to 3.32) 0.450 
Embryonic volume        
Trisomy 21 24 -27.76 (-35.80 to -19.72) <0.001 -3.45 (-4.56 to -2.34) <0.001 
Trisomy 18 17 -39.37 (-48.23 to -30.50) <0.001 -5.14 (-7.04 to -3.23) <0.001 
Trisomy 13 5 -40.87 (-59.75 to -22.00) 0.004 -5.25 (-8.63 to -1.88) 0.012 
Monosomy X 5 -27.29 (-55.56 to 0.0097) 0.055 -3.63 (-8.33 to -1.07) 0.097 
* For observed mean difference vs. 0. 
 
Table 2: Mean percentage difference for embryonic volume (EV) in aneuploid fetuses as a percentage of normal 
mean according to crown-rump length in euploid fetuses. 
Karyotype n Mean difference % 
(95% CI for mean) 
p* 
Trisomy 21 24 -0.37 (-8.56 to 7.83) 0.927 
Trisomy 18 17 -17.37 (-28.04 to -6.68) 0.003 
Trisomy 13 5 -9.75 (-31.78 to 12.28) 0.287 
Monosomy X 5 5.48 (-20.63 to 31.60) 0.591 
* For observed mean difference vs. 0. 
 
The difference between observed EV for the aneuploid fetuses and expected according to 
their CRL is presented in Table 2. Significant differences were found for fetuses affected by 
trisomy 18 which had on average a 17.37% smaller EV than the normal mean for CRL 
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Figure 2: First trimester measurements of crown-rump length (CRL) and embryonic volume (EV) according to 
gestational age in fetuses affected by trisomy 21 (first row) , trisomy 18 (second row) , trisomy 13 (third row)  and 
monosomy X (fourth row) , plotted on reference curves (mean solid line) and 95% reference interval (dashed line) 
for CRL and EV of euploid fetuses by Verwoerd-Dikkeboom et al.18 and Rousian et al.4, respectively. 
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(p=0.003). Smaller measurements of EV than expected for CRL were also found for trisomy 
13, although not statistically significant. For trisomy 21 and monosomy X, no difference was 
observed. 
 
Discussion 
The results of this study are in line with previous research demonstrating that chromosomal 
abnormalities are often accompanied by growth restriction. The data show that, based on 
CRL, growth restriction can be observed in trisomy 18 at 11-14 weeks’ gestation (-14.53%, 
p<0.001). Small, non-significant, differences in CRL were found for trisomy 13, monosomy X, 
and trisomy 21. In contrast to CRL, EV was significantly smaller than expected in trisomy 21, 
18 and 13, with a large but marginally non-significant difference in the small sample of 
fetuses with monosomy X. The mean percentage difference in EV was also more evident 
than the mean percentage difference in CRL, and was as high as -40.87% for trisomy 13. 
These findings show the same trend as the reported birth weight in these conditions: infants 
with trisomy 18 are most likely and those with trisomy 21 least likely to be small for GA 19. 
The EV is fetuses affected by trisomy 21 and 13 and monosomy X was found to be in 
proportion to their CRL, as no significant difference from that expected was found when EV 
was corrected for the observed CRL. However, disproportionate growth restriction was found 
in the fetuses with trisomy 18, when corrected for CRL, EV was significantly decreased (by 
17% on average). This disproportionality points to an asymmetric growth disturbance that 
affects the internal organs more than the skeleton, which is associated with more severe 
growth restriction. To further examine aspects of disproportionality, future research will be 
performed on the head-to-body volume ratio in both euploid and aneuploid fetuses in order to 
evaluate the type of growth restriction (symmetric or asymmetric).  
Structural congenital abnormalities are frequently present in chromosomally abnormal 
fetuses. As explained, we accounted for omphalocele and hydrops fetalis in the EV 
calculations. Holoprosencephaly, associated with trisomies 13 and 18, might have a small 
influence on EV. However, holoprosencephaly can be accompanied by both microcephaly 
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and hydrocephaly, each contributing to EV in a different direction. Moreover, it is unlikely that 
a 30-40% smaller EV is caused by structural abnormalities exclusively. Abnormal EV in 
aneuploid fetuses can be explained by an increased duration of the cell-cycle, due to 
checkpoint control genes, resulting in a significantly reduced numerical cell count compared 
to euploid fetuses 20.  
At present, it is only possible to speculate regarding the clinical importance of first-trimester 
growth restriction in aneuploid fetuses. It is as yet unclear as to whether first-trimester growth 
restriction is helpful in identifying fetuses with chromosomal abnormalities during the first 
trimester of pregnancy. It may, however, be hypothesized that markedly growth-restricted 
aneuploid fetuses are more prone to intrauterine fetal death in the second and third 
trimesters of pregnancy, and these pregnancies may be identified earlier by measuring EV. 
This hypothesis should be the subject of further research on EV and pregnancy outcome. 
Limitations of the study include the low number of cases for both trisomy 13 and monosomy 
X; the groups with the lowest incidence of the aneuploidies investigated in this study. 
However, the fact that we found a statistically significant difference in EV for trisomy 13 and 
only marginally non-significant difference for monosomy X (p=0.004 and p=0.055, 
respectively) suggests that there is a strong relationship between aneuploidy and decreased 
EV. It seems likely that analysis of additional cases in these groups would confirm the 
relationship. Another limitation of our study is that at this time the BARCO I-Space is too 
large (requiring a separate 40m2/400 sq. ft.) and too expensive for 3D VR becoming a routine 
diagnostic procedure, which limits routine practice. However, a desktop version of this 3D VR 
system is currently being developed, which will make this new and innovative technique 
more accessible to hospitals in the near future. A prototype is already being evaluated at our 
department for use in both research and daily clinical practice. 
In conclusion, evaluation of growth in the first trimester is typically performed by measuring 
CRL using 2D ultrasound. CRL can only be used as a reliable indicator of growth restriction 
in aneuploid fetuses in the first trimester for pregnancies with trisomy 18. Using EV, growth 
restriction is also evident in trisomy 21 and trisomy 13 and monosomy X. This study shows 
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that in aneuploid fetuses, EV measurements can be used to diagnose abnormal first 
trimester growth.
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 Objective: To demonstrate the use of a novel three-dimensional (3D) virtual reality (VR) 
system in the visualization of first trimester growth and development in a case of confined 
placental trisomy 16 mosaicism (CPM+16). 
Design: Case report. 
Setting: Prospective study on first trimester growth using a 3D VR system. 
Patient(s): A 34-year-old gravida 1, para 0 was seen weekly in the first trimester for 3D 
ultrasound examinations. 
Intervention(s): Chorionic villus sampling was performed because of an enlarged nuchal 
translucency (NT) measurement and low pregnancy-associated plasma protein-A levels, 
followed by amniocentesis. 
Results(s): Amniocentesis revealed a CPM+16. On two-dimensional (2D) and 3D ultrasound 
no structural anomalies were found with normal fetal Doppler’s. Growth remained below the 
2.3 percentile. At 37 weeks, a female child of 2010 g (<2.5 percentile) was born. After birth, 
growth climbed to the 50th percentile in the first 2 months. 
Conclusion(s): The I-Space VR system provided information about phenotypes not 
obtainable by standard 2D ultrasound. In this case, the delay in growth and development 
could be observed very early in pregnancy. Since first-trimester screening programs are still 
improving and becoming even more important, systems such as I-Space open a new era for 
in vivo studies on the physiologic processes involved in embryogenesis. 
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Introduction 
In this paper we describe a case of confined placental trisomy 16 mosaicism that was 
documented in detail in a prospective study on first trimester growth using three-dimensional 
(3D) Virtual Reality (VR)1. The aim of this paper was to demonstrate that by using this 
imaging technique, delay in both growth and development can be depicted, very early in the 
first trimester of the pregnancy. 
It is expected that as many as 1% 2 to 1.5% 3 of all (clinically recognized) conceptions may 
have trisomy 16, which is the most frequent chromosome abnormality at conception 4. In 
trisomy 16 an early embryonic arrest usually results in a miscarriage between 8 and 15 
weeks of gestational age. Trisomy 16 miscarriages show either empty sacs, disorganized 
embryos or minimal embryonic development 2. Almost all cases of trisomy 16 surviving in the 
second trimester of pregnancy are found to be mosaic (meaning that the cell lines contain 
both euploid and trisomic cells) 5. To survive, the mosaic trisomic 16 cell lines must be 
completely or at least predominantly confined to the placenta and this phenomenon is 
referred to as confined placental trisomy 16 mosaicism (CPM+16) 5. Robinson et al 6 found 
that most cases of CPM+16 originate during maternal meiosis I. The “rescue” means that a 
chromosome 16 is lost in one of the cells of the trisomic conceptus, resulting in an euploid 
cell line. This can be either one of the two maternal chromosomes 16, resulting in biparental 
disomy 16 (BPD 16) or the paternal chromosome 16, resulting in uniparental disomy 16 
(UPD 16) 7.  
Besides an increased risk for (severe) fetal malformations, CPM+16 is associated with intra-
uterine growth restriction, which is described in both BPD and UPD 16 cases 8,9. Early 
detection of placental confined trisomy 16 is important since patients are at increased risk for 
several maternal obstetrical complications, such as severe preeclampsia 10. The aim of this 
paper is to present a case of mosaicism trisomy 16 that caused an apparent delay in 
embryonic growth very early in pregnancy. 
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Case report 
A 34-year old gravida 1, para 0 participated in a prospective study to determine the 
beneficiary aspects of a novel imaging technique for optimizing first trimester visualization. 
Women enrolled in this study early in pregnancy, and a 3D ultrasound scan was made 
weekly from about 5 to 6 weeks of gestation till 13 to 14 weeks. This patient had an 
accurately documented first day of last menstrual period and a positive pregnancy test on the 
29th day of her cycle. On the first ultrasound examination, gestational sac, yolk sac and an 
indication of embryonic structures were visualized.  At eleven weeks, an increased nuchal 
fold was seen, possibly fetal hydrops. A sonographer licensed by the Fetal Medicine 
Foundation (FMF; Certificate of Competence in the 11+0 – 13+6 – week scan) carried out a 
nuchal translucency measurement 6 days later. The nuchal fold was 2.9 mm. The free β-
HCG level was 70.70 IU/ l (1.323MoM), and the pregnancy-associated plasma protein-A 
(PAPP-A) level was 0.013 IU/l (0,150 MoM; AutoDELFIA™ analyzer and LifeCycle™ Elips 
software-package, PerkinsElmer®, Wallac, Turku, Finland). The crown-rump length (CRL) 
was only 41.3 mm (the expected range for 12 weeks of gestation is between 46 and 63 mm). 
The corrected risk for trisomy 21, 13 &18 was 1 in 5. Following these results, a chorionic 
villus biopsy was performed. Five milligrams of chorionic villi were obtained, and in short-
term cultured villi an additional chromosome, most likely chromosome 16, was seen in all 
analyzed cells. To discriminate between CPM+16 and true fetal mosaicism of trisomy 16, 
amniocentesis was performed. Using fluorescence in situ hybridization with chromosome 16-
specific probes, normal signal distributions were noted in 100 uncultured amniotic fluid cells, 
and a normal female karyotype was seen in 37 colonies of cultured amniotic fluid cells. UPD 
16 was excluded. Since there still remains a residual risk on fetal congenital anomalies due 
to somatic mosaicism, the pregnancy was carefully monitored with two-dimensional (2D) and 
3D ultrasound, which revealed no structural anomalies; fetal Doppler remained normal. 
Growth of the fetus remained below the percentile 2.3 birth centile throughout the pregnancy. 
At 36 weeks, the patient was admitted into hospital for pregnancy-induced hypertension. At 
37 weeks, a caesarean section was performed for failed induction of labor. A female infant 
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was born with Apgar scores of 6 and 8 after 1 and 5 minutes. The infant had a birth weight of 
2010 grams (< 2.5 percentile). The placenta weighed 735 grams after fixation. Besides 
localized chorangiomatosis in one slice of the placenta, no abnormalities were found. The 
infant was monitored on the pediatric ward and was discharged 10 days after birth. 
The following year, the girl developed normally and her growth climbed to the 50th percentile 
in the first 2 months and remained there. No congenital abnormalities were found. 
 
Materials and Methods 
Two-dimensional and 3D ultrasound scanning was performed on a GE Voluson 730 Expert 
system (GE, Zipf, Austria). The 3D volumes were transferred to a personal computer for off-
line evaluation using specialized 3D software (4D view, GE Medical Systems). These data 
were transferred to the BARCO I-Space at the department of Bioinformatics of the Erasmus 
MC. This four-walled CAVE-like 11 VR system has been described in detail elsewhere 1,12-14. 
Using this system, we measured standard biometry such as CRL, biparietal diameter (BPD), 
occipito-frontal diameter (OFD), and calculated the head circumference (HC). We also 
established the Carnegie Stage of the embryo. The embryo was staged according to the 
description of the external morphological features, mainly limb development, of the Carnegie 
Stages illustrated and described by O’Rahilly and Müller 15. This method is described in detail 
in Verwoerd-Dikkeboom et al 1. 
 
Results 
The results of the biometry measurement (mean of three measurements) in the I-Space and 
the assigned Carnegie stages are displayed in table 1. 
The Carnegie Staging system ends at day 57 post conception, therefore when the patient 
was seen at gestational age 11 weeks + 1 day, assignment of Carnegie stages is no longer 
possible. 
120 
 
Table 1 
AGE (WEEKS) CARNEGIE STAGE (A) CRL(B) BPD OFD HC 
7+1 14 5.2 3.1 6.9 16.4 
8+1 16 9.6 6.5 11.1 28.1 
9+4 19 19.2 8 11.8 32 
11+1 -- 32.9 11.5 12.7 38 
12+0 -- 41.3 13.5 16.4 47 
(age is gestational age in weeks) 
Table 1 
Age is gestational age in weeks.  
(A)   The expected Carnegie Stage for that gestational age is given according to O’Rahilly and Müller 15, 
calculated as gestational age – 14 days to obtain the postovulatory age.  
(B)  The normal 5th-95th percentiles for that age are given for the different parameters. For CRL, the 
Robinson chart 23 was used, for BPD and HC the Kustermann charts 24 were used. 
 
Discussion 
Growth restriction 
Most case reports on CPM+16 (or other chromosomes) start with the result of the chorionic 
villus sampling (CVS) or amniocentesis. Therefore, little is known about embryonic and / or 
placental phenotypes in the first trimester of these pregnancies. This patient demonstrated 
growth retardation already very early in pregnancy. Very early growth retardation can be 
mistaken for gestational age discrepancy. Adjusting the gestational age could then have 
serious consequences. We encountered another issue related to very early growth 
aberrations: problems with performing proper first trimester screening. For first trimester 
screening most research describe both a gestational age period and CRL lengths. In first 
reports, this period was 10+0 - 14+0 weeks 16. Nowadays the FMF uses a 11+0 – 13+6 week 
period 17, corresponding with a CRL between 45 and 84mm. The First and Second Trimester 
Evaluation of Risk for Aneuploidy (FASTER) trial 18 used pregnancies with CRLs between 36 
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and 79 mm, corresponding with 10+3 – 13+6 weeks. At 11 weeks of gestation, our patient had 
a CRL of only 33 mm; at 12 weeks this was 42 mm, indicating that in the desired period of 
first trimester screening (11-13+6 weeks) the minimal CRL requirement according to the FMF 
is still not met. This implies that the effect of any delay in embryonic growth and development 
on the reliability of the results of combined first-trimester screening is unclear. 
PAPP-A 
The combined first-trimester screening for Down syndrome revealed that serum PAPP-A 
level in this patient was extremely low. Several studies have indicated the association 
between low levels of serum PAPP-A, with a number of adverse pregnancy outcomes, such 
as an increased risk of pre-eclampsia 17,18, gestational hypertension 18 and intra-uterine 
growth restriction17-19. Smith et al 20 stated in their study that this predictive value of PAPP-A  
implies a fundamental role of this system in the development of the placenta in early 
pregnancy.  This patient is a good example of the presumption that impaired placentation is 
reflected by low serum PAPP-A. To our knowledge, this is the first report that describes a low 
serum PAPP-A level in association with a placental confined trisomy 16. Groli et al 21 
described five cases of trisomy 16 confined to the placenta that were found after high-risk 
results in a second trimester maternal serum screening program for Down syndrome. 
Amniocentesis and CVS was performed. All five pregnancies displayed unusually high levels 
of hCG and four out of five had raised alpha-fetoprotein (AFP) values. All five pregnancies 
were complicated by fetal growth retardation. Other studies have also shown extremely high 
levels of hCG 2,22. Our patient, however, displayed an hCG level within the normal range on 
first-trimester screening; AFP level (26 IU/ml, measured at 16 weeks in amniotic fluid, normal 
range 15-30 IU/ml). 
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I-Space implementation 
We analyzed the 3D volumes of this patient in the I-Space, and we were able to easily 
measure and calculate CRL, BPD, OFD and HC using this system. We also established the 
Carnegie Stage of the embryo. The Carnegie Stage we assigned to this embryo 
corresponded very well with the measured CRL compared with the original data of the 
Carnegie Collection described by O’Rahilly and Muller 15, indicating that growth and 
development  were still in concordance. Delay in either growth or development would have 
meant that the assigned Carnegie Stages did not correspond with CRL measurements, for 
instance, a CRL measurement of a stage 21 embryo with morphological features of a stage 
19 embryo or the exact opposite, morphological features of stage 21 with CRL of stage 19.  
Age, however, did not correspond with CRL: the age discrepancy was more than 8 days in 
general. CRL parallels the Carnegie Stages in the discrepancy between CRL and gestational 
age. Since gestational age is not questioned in this patient, the only conclusion can be that 
both growth and development were delayed very early in pregnancy. The question is whether 
this can all be attributed to the placental confined mosaicism. If it is, it implies that 
placentation is already of vital importance in the earliest stages of pregnancy.  
We believe that it is essential to combine biometry measurements with evaluation of 
morphological features. The I-Space VR system provides us with information about 
phenotypes not obtainable by standard 2D ultrasound. In this case, the delay in growth and 
development could be observed very early in pregnancy. Since first-trimester screening 
programs are still improving and becoming even more important, we believe that systems 
such as the I-Space open a new era to study embryonic growth and development in vivo. 
This will eventually lead to better understanding of both physiologic and pathologic 
processes involved in embryogenesis.   
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Chapter 9 
General discussion 
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The aim of this thesis is to study the overall effectiveness of the combined first-trimester 
screening test for Down syndrome and other aneuploidies in the Dutch clinical setting and to 
determine the factors which are associated with the variation of the test performance. During 
the period in which parts of this research was conducted, the first-trimester screening test in 
The Netherland was extended in June 2010 by additional screening for trisomies 13 and 18. 
Furthermore, the no-invasive prenatal test (NIPT) was introduced in April 2014. 
We focused on the components of combined first-trimester screening, i.e., the biochemical 
and the sonographic components. In Part 1 the biochemical issues of first-trimester maternal 
serum screening are discussed. These are followed in Part 2 by a summary of the 
sonographic markers involved and related innovations in first-trimester screening for Down. 
In this thesis we concentrated on the following questions: 
1. Do the different methods of estimating gestational age affect reliability of first-
trimester screening for Down syndrome and other aneuploidies? 
2. Is there a difference in first trimester risk estimates for trisomy 21 and other 
aneuploidies, as calculated by two different software packages used in the 
Netherlands? 
3. What is the impact of laboratory manufacturing differences in of the concentration 
of the pregnancy-associated plasma protein A (PAPP-A) on the test performance 
of first-trimester screening (FTS) for Down syndrome and other aneuploidies?  
4. What is the prevalence of detectable jugular lymphatic sacs in a setting for first 
trimester screening of Down syndrome, and is there an effect of jugular lymphatic 
sacs on the screening performance for chromosomal abnormalities? 
5. Is there an added value of incorporating additional first trimester markers to an 
extensive risk assessment for aneuploidy screening in the first trimester?    
6. What is the difference in growth patterns of aneuploid fetuses (trisomy 21, 18, 13 
and X0) during the late first trimester using a 3D Virtual Reality (VR) system? 
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All studies were done on prospectively collected data of our first-trimester screening 
population, attending the out-patient clinic of the division of Obstetrics and Prenatal Medicine 
at Erasmus University Medical Center, Rotterdam, The Netherlands. Research questions 
were formulated based upon findings that were encountered during the first-trimester 
screening program and known from the relevant literature at the time of the studies. 
The topics being elaborated in this discussion are the influence of the biochemical screening, 
ultrasound screening and the combination of those two in the first-trimester screening 
program. Furthermore the future of the first-trimester screening program for Down syndrome 
and other aneuploidies will be discussed. 
 
In January 2007 the national program for prenatal screening for Down Syndrome has been 
implemented in the Netherlands1. For this purpose, the first-trimester combined screening 
(FTS) test was advocated. First-trimester screening by means of the combined test (CT) for 
the detection of Down syndrome (trisomy 21) is offered to all pregnant women. This test 
encompasses the assessment of two biochemical markers in maternal serum, i.e. free beta 
human chorionic gonadotropin (free β-hCG)  and  pregnancy-associated plasma protein A 
(PAPP-A), and the sonographic assessment of the fetal nuchal translucency (NT). 
Combining these three markers, together with maternal age, 76-91 % of the pregnancies with 
trisomy 21 can be detected with a 3-7% false positive rate 2-5. First-trimester screening in the 
Netherlands was expanded to screening for trisomies 13 and 18 in June 2010. 
 
The value of maternal serum markers, i.e., pregnancy-associated plasma protein-A (PAPP-
A) and free ß-human chorionic gonadotropin (free β-hCG) has been determined in large 
studies. In affected pregnancies the median level of free beta-human chorionic gonadotropin 
(free β-hCG) was 1.79 times the median level for unaffected pregnancies. The other marker, 
PAPP-A, was 0.43 times the normal median 6-9.  Additionally low levels of first-trimester 
maternal serum PAPP-A are also shown to be predictive of other fetal chromosomal 
abnormalities, such as trisomy 13 and 18, triploidy and sex chromosome aneuploidy.   
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The blood sample for the maternal serum screening has to be taken between 8+4 to 13+6 
weeks’ gestation. Studies have demonstrated that the combined FTS test performs best 
when the maternal blood sample is taken at 10 weeks gestation 10 and the measurement of 
NT is performed at 12 weeks 11. All maternal serum samples were analyzed with the 
AutoDELFIA analyzer (Perkin Elmer Life Science, Boston, MA, USA) and commercially 
available kits. The calculations of the maternal-weight-corrected MoMs of the biochemical 
markers were done using the LifeCycle-Elips software (Perkin Elmer Life Science, Boston, 
MA, USA).  
As demonstrated in Part 1 of this thesis the biochemical screening in the first-trimester is an 
area in which small differences may have large consequences. Considerable differences in 
pregnancy dating can be found, even in women who reported a regular menstrual cycle. 
Because the missing - or the lack of reliable -  information, LMP cannot be used in an 
estimated 40% of the eligible women 12. 
Hence, dating by means of ultrasound in early pregnancy has become a valid way of 
estimating gestational age. The test performance is dependent on a consistent and 
standardized determination of all parameters and is only applicable in a relatively small time 
frame. To allow for systematic changes in serum levels of PAPP-A and free β-hCG with 
changing gestational age, serum concentrations are converted into multiple of the normal 
median (MoM) at a given gestational age. Calculations of the maternal-weight-corrected 
MoMs of the biochemical markers depend on reliable determination of gestational age. 
Different methods of estimating gestational age do affect reliability of first-trimester screening 
for Down syndrome. The use of ultrasound to estimate gestational age in normal 
pregnancies improves the sensitivity and specificity of maternal serum screening 13,14. 
However, as in measurement of NT there should be a reliable measurement of the CRL as 
both NT and biochemical screening algorithms are CRL depended 15,16. Typically, growth 
restriction in aneuploid pregnancies is of early onset, and is evident from the first trimester 
onwards. In trisomy 21, however, crown-rump length (CRL) measurements are similar to 
chromosomally normal fetuses of the same gestational age (GA) 17-19. Growth restriction can 
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be observed in trisomy 18 at 11-14 weeks’ gestation. Though small, non-significant, 
differences in CRL are observed in trisomy 13, monosomy X, and trisomy 21 20. For the final 
risk estimation, the ultrasound data and the results of the maternal serum analysis of the free 
β-hCG and PAPP-A can be combined in the Fetal Medicine Foundation£  (FMF) module in an 
obstetrical software database (always using the latest available version of Astraia ®, Astraia 
Software GmbH, München, Germany). However if the FMF module or stand-alone FMF 
software is not available for sonographers these calculations can be made by the laboratory 
using the Wallac-Perkin-Elmer£software in LifeCycle-Elips (Perkin Elmer Life Science, 
Boston, MA, USA). Risk estimates derived from each software program appeared to be 
strikingly different. There is a discrepancy in reported size of risk resulted from disparities 
between the two calculation methods for the assessment of the individual risk for trisomy 21. 
The disparities in risk estimates can be explained by significant differences in reported 
likelihood ratio’s for biochemical analyses (p=0.01), NT measurements (p<0.0001) and both 
screening parameters combined (p=0.003).  Manufactures constantly update software 
packages without fully informing those who are involved in prenatal counselling and 
screening about the changes made in their new releases. From the public health point of 
view, first-trimester screening for trisomy 21 and other aneuploidies should be preferably 
done in a standardized way. For this purpose ‘harmonization’ was introduced in the 
Netherlands. However, this is only applicable on biochemical analyses of the maternal 
serum. There is no check on applied gestational age and the calculation of the combined risk 
is done in the LifeCycle or in the FMF software.  
The fact that even fully implemented harmonization is not always reliable, is shown by the 
fact that between the 7 laboratories, which perform the biochemical testing in the 
Netherlands, differ in their methodological approach. According to the national reference 
laboratory of the RIVM, half of the laboratories use the DELFIA Xpress® analyzer 
(PerkinElmer, Turku, Finland) and the other half makes use of the AutoDELFIA® analyzer 
(PerkinElmer, Turku, Finland). However, all are dependent on commercially available kits, 
produced by the same manufacturer PerkinElmer (Turku, Finland). The fact that this small 
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difference in harmonization was a turn for the better, is demonstrated when an erroneous 
PAPP-A kit for the DELFIA Xpress® analyzer was produced and a 20% downward shift in 
concentrations with a five percent increase in monthly screen-positive findings was found. 
Corrections and re-assessment of the maternal serum samples could be performed by the 
national reference laboratory of the RIVM, which uses the AutoDELFIA® analyzer. Strangely 
enough, no other laboratory with the DELFIA Xpress® analyzer reported similar findings in a 
downward shift of PAPP-A concentrations or an increase in false positive findings in the 
described period. 
 
In Part 2 we described different ways of introducing different ultrasound techniques into the 
FTS-test and their additional value. First and foremost, these sonomarkers or techniques 
should be independent, i.e., not be interrelated. Nuchal translucency (NT) is portrayed as 
subcutaneous fluid accumulation in the neck region of unknown origin. Although many 
theories have been put forward a common morphogenesis explaining the interrelationship 
between the complete spectrum of fetal malformations and enlarged NT is still lacking. 
Earlier studies 21 described the development of the Jugular Lymphatic Sacs (JLS) preceded 
the NT and that the JLS showed distension just prior to the occurrence of the increased NT 
22-24. However they were not able to give conclusive evidence on the question if JLS 
precedes NT or visa-versa. In this thesis we concluded that visual JLS significantly predict 
chromosomal abnormalities, although NT is a better predictor. In terms of test performance, 
however, the additional value of combined testing is limited as both predictors are 
interrelated.  
The assessment of the fetal NT in combination with maternal blood sampling has shown to 
be an accurate and sensitive screening test for trisomy 21 and other aneuploidies with a 
sensitivity of 90% and a specificity of 95% 4,19,25,26.  
The sensitivity of this way of screening has shown to be superior to that achieved by 
maternal age alone (44%) and the second trimester serum biochemistry (60%). Studies from 
specialist centers have demonstrated that, in addition to NT, absence of nasal bone 27,28 
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(sensitivity 60-70% and specificity 98%), increased impedance to flow in the ductus venosus 
29 (sensitivity 80% and specificity 95%) and tricuspid regurgitation 30 (sensitivity 70% and 
specificity 95%) are other highly sensitive and specific first trimester sonographic markers of 
trisomy 21 31. This innovative first-trimester screening by adding multiple so called 
sonomarkers may achieve higher detection rates among women at intermediate risk (>1 in 
999 and <1 in 50) than screening by combination test alone (Sonek and Nicolaïdes reported 
detection rates by using two markers 94%, three markers 95%, and four markers 96% at a 
false positive rate of 2%) 32.  
 In this thesis we tested these four sonomarkers in a clinical trial of 30 months with an 
intermediate risk after first-trimester combined screening, i.e., a risk of > 1:200  to <1:50.  
All women included in our study population were offered invasive diagnostic testing such as 
chorionic villus biopsy or amniocentesis. Some of these women, however, were reluctant to 
have invasive testing because these tests are associated with a risk of iatrogenic miscarriage 
(0.3-0.5%) 33-38. Additional sonographic markers have been identified to assess the risk of 
trisomy 21, 18 and 13 in the first trimester of pregnancy. This approach, the so-called 
combined test ‘plus’ (CT-plus) has been used as a second-tier test following FTS. In this 
study we evaluate the additional value of CT-plus examination in patients with an 
intermediate risk of trisomy 21, 18 and/or 13 after the first-trimester combined test with 
respect to outcomes (karyotyping). The CT-plus ultrasound examinations were performed 
following the strict methodological criteria set by the Fetal Medicine Foundation (FMF®). CT-
plus is a tool that can be used for decreasing the false-positive rate after the FTS. The 
decrease in screen-positive rates may lead to fewer invasive procedures and in that way 
prevents iatrogenic miscarriages. However, the additional value of the assessment of 
sonomarkers is limited, since it is associated with a low detection rate of fetal aneuploidy 
(sensitivity 25%).  
In addition to the first trimester sonomarkers new ultrasound techniques have been 
introduced in the last decade. Because aneuploidy is associated with fetal growth restriction 
39-44, already present from the first trimester of pregnancy onwards, three-dimensional (3D) 
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ultrasound can be used to measure Embryonic Volume (EV) in addition to crown-rump length 
(CRL). EV seems to be a more accurate parameter to assess first trimester growth restriction 
in aneuploid fetuses. The introduction of the Virtual Reality (VR) visualization technique 
enables us to use all three dimensions of these 3D US scans 45. CRL growth restriction may 
be observed in trisomy 18 although this is less clear in fetuses with trisomy 13, monosomy X 
and trisomy 21 39,40,42. In contrast to CRL, EV is significant smaller in trisomy 21, trisomy 18 
and trisomy 13. Therefor EV measurements may be used to diagnose abnormal first 
trimester growth. This is also shown in the case report on a placental confined trisomy 16 we 
presented. Early fetal growth restriction was detected by 2D, 3D and EV measurements.  
Chorionic villus sampling (CVS) and amniocenteses will remain the gold standard for 
detecting fetuses with chromosomal anomalies. Invasive diagnostic testing, however, is 
associated with an increased risk of miscarriage 33-37. Screening by means of the FTS- test 
has been a proven and reliable alternative, providing that the test is executed in standard 
way. Since April 2014 NIPT is accessible in case of increased risk for aneuploidies 46. 
The use of the sonographic markers requires accurate examination by highly skilled 
operators and is time consuming and should be restricted to specialist centers. 
The use of 3D and VR is a useful tool for detection of structural anomalies in early pregnancy 
(6-12 weeks). Especially in case of X-linked, dominant or recessive inherited anomalies of 
the brain (for instants X-linked hydrocephaly or Meckel-Gruber syndrome), anomalies of the 
skull (for instants Adams-Oliver syndrome, cranio-fronto-nasal dysplasia, Carpenter 
syndrome) and anomalies of the limbs (such as TAR syndrome, SHSF syndrome, oral-facial 
digital syndrome and many others). EV however could be a real asset in first-trimester 
screening for Down syndrome and other chromosomal or structural anomalies, although this 
technique needs more research. It has proven its value in diagnosing early growth restricted 
fetuses, which is associated with chromosomal abnormalities and pregnancy complications 
such as early fetal demise and IUGR. The addition of the VR technique is already being 
developed into an application that can be used as a desktop 45 and the value of 3D 
ultrasound and EV are shown in the last chapter in which we describe a case diagnosing of 
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trisomy 16. In this case very early growth restriction was found by 3D and EV next to an 
enlarged NT and abnormal results of maternal serum sampling. Throughout the pregnancy 
the fetus was assessed for structural anomalies by 2D and 3D ultrasound. None were 
diagnosed.   
The future of the FTS-test in screening for aneuploidies is to be discussed because of new 
developments in Non-Invasive Prenatal Tests (NIPT). Since the end of the nineteen nineties 
the research in cell-free fetal DNA in maternal serum has taken a flight 47. In the Netherlands 
is has already been used for genotyping fetal rhesus-D and early pregnancy gender typing, 
in case of gender confined recessive genetic anomalies. In the area of detecting trisomy 21 
and 18 much progress has been made. NIPT is a highly sensitive test for trisomy 21 in 
comparison with the first-trimester screening test. False positive results of NIPT are 
estimated less than 0.3%, which gives a test specificity of 99,7% 48. The positive predicting 
value of this test, however, is reliant on the a priori risk of the pregnant woman. The higher 
the a priori risk, the higher the positive predicting value. However, in case of an unfavorable 
NIPT outcome, confirmation by invasive testing is currently required for validation purposes. 
NIPT has a failure rate of 3%, i.e. no definitive result is possible. This is more likely in women 
with a high body mass index (BMI). Furthermore the validation in multiple pregnancies is still 
controversial 49. International studies have proven the reliability of NIPT 48 even in a low-risk 
population 50. In the Netherlands NIPT is since April 2014 available, but only in case of an 
increased risk for chromosomal anomalies after FTS. In the future NIPT may be available for 
other genetic and congenital anomalies 51. 
Even though the screening for aneuploidies by means of the first-trimester screening test 
could slowly become replaced by non-invasive karyotyping 52-57, the assessment of early 
pregnancy ultrasound screening by 2D and 3D ultrasound and use of Doppler, in 
combination with EV techniques, will be valuable in early screening for structural 
malformations. It is known that an abnormal flow in the ductus venosus, an abnormal flow 
over the tricuspid valve and an increased NT thickness are associated with cardiac defects, 
other structural anomalies and poor pregnancy outcome (miscarriage or intrauterine demise) 
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58-68. Recently, the measurement of low-resistance flow in the hepatic artery in addition to the 
tricuspid regurgitation and abnormal ductus venosus flow, has become an added screening 
instrument for chromosomal abnormalities, genetic syndromes and structural anomalies 69,70. 
The majority of significant structural defects are already detectable at this point in pregnancy 
32,71,72. With the use of additional biomarkers, like placenta growth factor (PLGF) and alpha-
fetoprotein (AFP), not only increase the detection rate (DR) (87.9%) and lowers the false 
positive rate (FPR) (1.8%) in first-trimester screening for aneuploidies 73,74, but are shown 
useful in first-trimester screening for pre-eclampsia, fetal growth restriction and preterm birth 
75-78. Nowadays a great deal of research is being done on risk assessment for pre-eclampsia, 
preterm labour, intrauterine growth restriction, macrosomia and gestational diabetes.  
It is not likely that in the near future the first trimester screening will be replaced by NIPT. The 
ultrasound scan at 11-14 weeks is not just for measurement of CRL and NT. It can be and is 
more frequently used for meticulous check of fetal structures and early diagnosis of major 
fetal abnormalities 79. The use of NIPT should be used complementary to the existing 
strategy of first-trimester ultrasound and biochemistry 74.  
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Summary  
The overall aim of the thesis is to describe the first trimester screening test for Down 
syndrome and several methodological issues. This first-trimester screening test combines 
biochemical screening of maternal serum and ultrasound screening. In this way both subsets 
of combined screening depend on interpreting measurements for the individual’s risk of 
Down syndrome, thereby taking into account maternal age. The test performance is highly 
dependent on a consistent and standardized determination of parameters and is only 
applicable in a relatively small time frame. Reliability is an important characteristic of a 
screening test. Reliability is synonymous to reproducibility, repeatability, transferability, 
precision and consistency. These terms refer to the degree of stability when a measurement 
is repeated under the same conditions. In this thesis we present several studies which 
describe some methodological issues of the first trimester screening for Down syndrome by 
using ultrasound markers and maternal serum markers and the combination of these 
markers in order to provide more insight in the day to day use of the first trimester screening 
test. 
Chapter 1 describes how the first trimester combined test consists of the measurement of 
the fetal nuchal translucency measurement, or NT, and combination of this ultrasound 
marker with the maternal serum component, which involves the determination in the maternal 
serum of two placentally derived biochemical markers. By a mathematical algorithm, these 
measurements adjust the maternal age related risk of Down syndrome at the time of testing. 
This approach of testing is used in a screening setting. Screening is aimed at asymptomatic 
(low risk) populations and helps to distinguish between high risk and low risk. The success of 
the test depends on the reliability of the test itself, the sensitivity and specificity of the test 
and the execution of the test.   
 
Part 1: Biochemical issues in the first-trimester screening test 
Chapter 2 deals with the dating of a pregnancy. The first-trimester screening test combines 
the woman’s a priori risk of Down syndrome with the NT and the findings of maternal serum 
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screening. The test performance of the combined first-trimester screening test is optimal in 
the relatively short time frame from 11+0 to 14 weeks’ gestation, which corresponds with a 
crown-rump length (CRL) of 45 to 84 mm. Since all markers of the first-trimester screening 
test for Down syndrome vary with gestational age, the estimates of free β-hCG and PAPP-A 
are converted to a multiple of the expected normal median (MoM) to adjust for the effect of 
gestational age, while values for NT are derived from information of CRL at the time of NT-
measurement. Therefore correct dating of the pregnancy is crucial for the assessment of the 
individual risk of Down syndrome. Dating by means of ultrasound in early pregnancy has 
become an accepted way of estimating gestational age. Provided fixed values for NT are 
applied, dating-scans reduce the number of screen-positive findings on the basis of 
biochemical screening. For the implementation of policy guidelines for Down syndrome 
screening it is recommended to use CRL-dependent parameters rather than LMP-dependent 
parameters of gestational age. 
In Chapter 3 our study shows the outcome of individual risk assessment for Down syndrome 
by using the commercially available software packages. The result of the first trimester 
combined screening is calculated by a mathematical model, thereby taking in account the 
maternal age-related a priori risk of the eligible women, the observed estimation of likelihood 
ratios (LRs) derived from maternal serum levels of the markers, free β hCG and PAPP-A, 
and the NT. This study shows that with the same screening parameters, marked disparities 
were observed between numerical risk estimates derived from the Fetal Medicine Foundation 
(FMF) software package and those derived from Wallac-Perkin-Elmer£software (Lifecycle). The 
different software packages with their underlying algorithms have an impact on the quality of 
testing by influencing sensitivity, specificity, and the positive and negative predicting values. 
Risk estimates based on the combination of maternal age, biochemical findings and NT 
measurements were for most women strikingly different. However, major disparities arise 
with outliners, which are affected by disparate use of truncation limits. These resulting 
differences in risk estimates could have a major emotional impact on the woman. In fact, 
both caregivers and couples felt at loss with these discrepant test results. Software 
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manufacturers are not transparent with regard to the truncation limits used. It is illustrated 
that the lack of agreement between these risk calculation methods could give rise to major 
counselling problems. 
In Chapter 4 we describe the impact on FTS performance of an approximately 20% 
downward shift in the PAPP-A concentrations due to the erroneously produced PAPP-A kits 
used for the FTS test for Down syndrome. In the Netherland seven laboratories are 
responsible for the assessment of the biochemical first-trimester serum markers. For a short 
period of time in 2009 a downward shift in concentrations of PAPP-A was observed by the 
laboratory quality institute UK-NEQAS and prenatal screening centres in the region 
expressed their concern about the increase in number of screen positive findings following 
combined risk calculation they encountered in the last months. Our study evaluated the 
potential clinical consequences of this impact and concluded that the consequences of 
erroneous low PAPP-A and thereby an increased biochemical risk calculation were 
considerable. Of the total study group 5% had an invasive procedure that was based on an 
incorrect increased combined risk estimate. Fortunately this has not resulted in reported 
iatrogenic miscarriages. Both laboratories and manufacturers need to evaluate their own 
performance critically and take all possible measures to ensure that they are providing high-
quality risk estimates based on maximum precision. Very important are the UK-NEQAS 
reports in this quality assessment. However, health care professionals in the field of prenatal 
screening of Down syndrome are still accountable for the implementation of the FTS. A 
frequent audit of the distribution of the biochemical markers free β-hCG and PAPP-A 
alongside with the distribution of NT is advocated.  
 
Part 2: ultrasound issues in first-trimester screening for Down syndrome 
Chapter 5. Measurement of the NT and the combination with maternal serum sampling in 
the first trimester screening for Down syndrome has become standard in Dutch antenatal 
care. The explanation of the relationship between the complete range of fetal malformations 
and an enlarged NT is still lacking. The entity of an enlarged NT and the presences of 
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abnormal development of Jugular Lymphatic Sacs (JLS) have been described in many 
studies, hypothesizing that a disturbance in lymphatic growth precedes an enlarged NT and 
could be an early prognostic sign. In an observational study the prevalence and detectability 
of JLS were investigated. Furthermore, the potential of JLS as an early marker for Down 
syndrome was tested. In this context, the prerequisite for adding JLS to first trimester 
measurement of the nuchal translucency is its independent association with chromosomal 
abnormalities. The absence of JLS in early pregnancy could perhaps be used as a 
sonographic marker for ruling out chromosomal abnormalities (negative predictive value). 
However the ability to detect JLS is limited by the spatial resolution of ultrasound machines. 
The sonographic visualization of JLS smaller than 2.0 mm is time consuming and requires 
specially trained and highly skilled ultrasound operators. The additional value of combined 
testing is limited as both predictors are interrelated. 
Chapter 6. The first-trimester screening test is widely used and acknowledged method for 
the assessment of the risk of fetal aneuploidy.  Women are considered “screen positive” 
when the test result indicates an increased risk of trisomy 21, 18 and/or 13 i.e. risk > 1 in 
200. These patients are offered an invasive diagnostic test such as chorionic villus biopsy or 
amniocentesis. Some of these women, however, are reluctant to have invasive testing 
because these tests are associated with a risk of iatrogenic miscarriage (0.3-0.5%). In this 
chapter we evaluate the additional value of CT-plus examination in patients with an 
intermediate risk (>1 in 200 and <1 in 50) of trisomy 21, 18 and/or 13 after the first-trimester 
combined test. These markers include the nasal bone, fronto-maxillary facial angle, ductus 
venosus, and tricuspid valve Doppler evaluation. This approach, the so-called combined test 
‘plus’ (CT-plus) has been used as a second-tier test following first-trimester screening. The 
CT plus is a tool that can be used for decreasing the false-positive rate after the first 
trimester combined test,  The decrease in screen-positive rates may lead to fewer invasive 
procedures and in that way prevents iatrogenic miscarriages. However, the assessment of 
these specific sonomarkers coincided with a decreased detection rate of trisomy 21 and 18, 
making its additional value quite limited among this specific category of women. 
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Chapter 7. Aneuploidy is associated with fetal growth restriction already present from the 
first trimester of pregnancy onwards. With three-dimensional (3D) ultrasound it is possible to 
measure Embryonic Volume (EV) in addition to crown-rump length (CRL). In this chapter we 
examined whether EV is a better predictor of growth restriction in aneuploid fetuses. 
Traditionally, first trimester fetal growth has been documented by two-dimensional (2D) CRL 
measurements. With the introduction of three-dimensional (3D) ultrasound (US) it became 
possible to measure embryonic and fetal volumes. The relative increment of fetal volume is 
much larger than the increment of CRL during the same period. Using V-Scope it is possible 
to perform several biometric measurements, like CRL and EV, in the I-Space benefiting from 
the true 3D depth perception. CRL, the golden standard, can only be used as a reliable 
indicator of growth restriction in aneuploid fetuses in the first trimester for pregnancies with 
trisomy 18 (-42.5%). Using EV, growth restriction is also evident in trisomy 21 (-28%) and 
trisomy 13 (-43.4%). In monosomy X a non-significant smaller (-35.5%) EV was found. The 
atypical volume of aneuploid fetuses may be explained by an extended cell cycle under 
influence of so called checkpoint control gens, resulting in a significant smaller number of 
cells compared to an euploid fetus. This study shows that in aneuploid fetuses EV 
measurements may be used to diagnose abnormal first-trimester growth. 
Chapter 8 The additional value of 3D sonography and I-Space innovation is discussed in a 
well-documented case of “confined placental trisomy 16 mosaicism”. The patient enrolled in 
a study early in pregnancy and a 3D ultrasound scan was made weekly from about 5 to 6 
weeks of gestation till 13 to 14 weeks in which measurements were taken and anatomical 
futures (particularly the development of the limbs) were compared to embryonic development 
described according the Carnegie Stages. In this case there was a discrepancy in gestational 
age based on a certain last period, sonographic measurements and development. Besides 
the growth restriction there was an enlarged NT and a low PAPP-A concentration. Additional 
invasive diagnostic tests (CVS and amniocenteses) revealed a placental confined trisomy 16 
mosaicism. Growth and development were strictly followed up by 2D and 3D ultrasound. No 
anomalies were found and growth stayed symmetrical small for gestational age. The 3D 
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ultrasound and assessment in I-Space clearly contributed to the early detection of intra 
uterine growth restriction and development in a fetus with an uncommon chromosomal 
anomaly. We believe that systems such as the I-Space open a new era to study embryonic 
growth and development in vivo. 
In the general discussion, the last part and chapter 9 of this thesis, the results of all studies 
are discussed and combined in a broader perspective. Our goal was to discuss the 
methodological issues of first-trimester screening (FTS) and the impact of small changes 
within the biochemical and ultrasound components, and the application in the day to day 
practice. Alongside the new ultrasound techniques of 3D and Virtual Reality are discussed. 
With the introduction of the non-invasive prenatal test (NIPT) the importance of FTS has 
hardly changed. If the result of FTS shows an increased risk for trisomy 21, 13 and/or 18 of 1 
in 200 of more, there is now the possibility to choose for the NIPT, besides the known 
invasive diagnostic testing (chorionic villus sampling or amniocenteses) without the risk of a 
miscarriage due to the invasive techniques. 
 The ultrasound scan between the 11th and 14th week of gestation is not just for 
measurement of the CRL and NT. It can and has become more and more a first structural 
scan of fetal structures and a tool for early diagnosis of major fetal anomalies. The 
application of fetal Doppler sonomarkers has proven its value in early detection for congenital 
heart defects.  
The possibility of NIPT should be used complementary to the existing strategy of first-
trimester ultrasound and biochemistry.  
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Samenvatting 
Dit proefschrift heeft als doel het beschrijven van de eerste-trimesterscreeningtest voor 
downsyndroom en een aantal methodologische facetten. Deze test, ook wel combinatietest 
genoemd, bestaat uit twee verschillende onderdelen: een biochemisch deel en een 
echoscopisch deel. Beide delen, en daarmee ook de combinatie ervan, zijn afhankelijk van 
het op een juiste manier hanteren van bepalingen en berekeningen van de individuele kans 
op downsyndroom. Bij de berekening wordt de leeftijd van de betrokkene verdisconteerd. De 
testeigenschappen berusten op een consequente en gestandaardiseerde meting van 
variabelen die alleen binnen een relatief kort tijdsbestek worden uitgevoerd. De 
betrouwbaarheid van een screeningstest, en daarmee de sensitiviteit en specificiteit, is 
verwant met reproduceerbaarheid, herhaalbaarheid, overdraagbaarheid, precisie en 
consistentie. Deze termen verwijzen naar de mate van stabiliteit als een meting wordt 
herhaald onder dezelfde omstandigheden. In dit proefschrift presenteren we studies die een 
aantal methodologische facetten van de eerste-trimesterscreening voor downsyndroom met 
behulp van echoscopische markers en maternale serummarkers, en de combinatie van deze 
markers, evalueert om meer inzicht te krijgen in de dagelijkse toepasbaarheid van de eerst-
trimesterscreeningtest. 
In hoofdstuk1 wordt beschreven hoe de eerste-trimestercombinatietest is opgebouwd uit de 
meting van de foetale nekplooi, of wel nuchal translucency (NT), en combinatie van deze 
echoscopische bepaling met de biochemische component, bestaande uit de bepaling in het 
maternale serum van twee eiwitten. Deze metingen zetten de leeftijdsspecifieke kans voor 
downsyndroom om in een zwangerschap specifieke ofwel gecorrigeerde kans. Deze testen 
worden in screeningssetting gebruikt. Screening heeft betrekking op asymptomatische 
(laagrisico) populaties en helpt een onderscheid te maken tussen hoog risico en laag risico. 
Het succes van de test is afhankelijk van de betrouwbaarheid van de test zelf, de sensitiviteit 
en specificiteit en de uitvoering van de test.  
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Deel 1: Biochemische kwesties in de combinatietest 
In hoofdstuk 2 wordt de invloed van het dateren van een zwangerschap op de 
betrouwbaarheid van de eerste-trimesterscreeningstest voor downsyndroom of 
combinatietest besproken. De screeningtest moet worden uitgevoerd tussen de 
zwangerschapsduur van 11 tot 14 weken die overeenkomt met een kruin-stuitlengte of 
Crown Rump Lengh (CRL) van 45-84 mm. Aangezien alle markers van de combinatietest 
variëren met de zwangerschapsduur, worden de waardes van free β-hCG en PAPP-A 
omgezet naar een zgn. ‘multiple of the expected normal median (MoM)’ om te corrigeren 
voor zwangerschapsduur, terwijl de NT-meting afgezet wordt tegen de CRL ten tijde van de 
meting. Het correct dateren van de zwangerschap is daarom van cruciaal belang voor het 
berekenen van de zwangerschap specifieke kans op downsyndroom. Het is aan getoond dat 
echoscopie in de vroege zwangerschap meer betrouwbare informatie oplevert om de 
zwangerschapsduur vast te stellen. Bij gebruik van vaste NT-waardes kunnen 
termijnbepalingen het aantal foutpositieve uitslagen reduceren. Implementatie van een 
richtlijn om bij de screening op downsyndroom de zwangerschapsduur op basis van CRL in 
plaats van LMP te gebruiken, wordt aanbevolen. 
Hoofdstuk 3 laat zien dat de commerciële softwarepakketten die worden gebruikt voor de 
berekening van de kans op downsyndroom tijdens het eerste trimester van de zwangerschap 
niet altijd leiden tot hetzelfde resultaat. De kans op een kind met downsyndroom wordt 
berekend op basis van de uitgangkans (a priori kans) passend bij een maternale leeftijd, in 
combinatie met de echoscopisch gemeten foetale nekplooidikte en de verhoudingen van 
twee door de placenta geproduceerde eiwitten, free β hCG en PAPP-A, in het moederlijk 
serum. In dit hoofdstuk wordt aangetoond dat ondanks gelijke screeningparameters de 
berekenende kansen bij het softwarepakketten van de Fetal Medicine Foundation (FMF) en 
die van Wallac-Perkin-Elmer£software ( LifeCycle) verschillende uitkomsten opleveren. De 
verschillende software pakketten, met hun onderliggende algoritmes, hebben een impact op 
de testeigenschappen in de vorm van sensitiviteit, specificiteit, positieve en negatieve 
voorspellende waarden. Voor de grootste groep van de bepalingen zal er geen uitgesproken 
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verschil te detecteren zijn. Maar bij de uiterste, de zgn. ‘uiteinden of afkappunten (truncaties)’ 
van de spreiding van de bepaalde waarden zijn de verschillen soms aanzienlijk. Dit kan, bij 
diegene die mogelijk onterecht in de hoog risico zone zijn gekomen, lijden tot onnodige 
ongerustheid bij de aanstaande ouders. De fabrikanten van de softwarepakketten zijn niet 
transparant over de limieten en redenen van de gehanteerde afkappunten. Verschillen in 
risicoberekeningen kunnen worden teruggevoerd op significante verschillen in gehanteerde 
likelihood ratio’s van de biochemische analyse, NT meting en de combinatie van beide 
parameters. Het is illustratief voor het gebrek aan overeenkomst tussen de risicoberekening 
methoden en kan voor grote problemen zorgen bij de counseling omdat het niet duidelijk is 
wat de feitelijke individuele kans is.  
In Hoofdstuk 4 wordt de impact van een 20% daling van de PAPP-A concentraties ten 
gevolge van een productiefout in de PAPP-A bepalingsets op de prestatie van de 
combinatietest beschreven. In Nederland zijn zeven laboratoria belast met de bepaling van 
de eerste-trimester serum screening. Gedurende een korte periode in 2009 werden door 
aangesloten centra voor prenatale screening en het UK-NEQAS een toename van het aantal 
foutpositieve bevindingen en een verlaging van de mediaan in de PAPP-A waardes 
waargenomen. De studie evalueerde de potentiële consequenties van de impact en 
concludeerde dat de consequenties van de foutief lage PAPP-A waarden en daarmee de 
verhoogde biochemische risicoberekening aanzienlijk. Op de hele studiegroep had 5% een 
invasieve ingreep op basis van een niet correct gecombineerde risicoberekening. Gelukkig 
waren er geen iatrogene miskramen na deze ingrepen gemeld. Deze studie toont aan dat 
continue en strenge controle van de kwaliteit van de eerste-trimsterscreeningstest van groot 
belang is. 
 
Deel 2: Echoscopische kwesties in de combinatietest  
Hoofdstuk 5. Er zijn veel theorieën over het ontstaan van de verdikte nekplooi. In studies 
werd aangetoond dat een verstoring van de ontwikkeling van het lymfvatenstelsel en 
daarmee een verdikking van de lymfvaatzakjes (Jugular Lymphatic Sacs of JLS), voorlopers 
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van de lymfknopen, in de nek regio, vooraf gaat aan een verdikte nekplooi. Voortbordurend 
op die hypothese zou het kunnen zijn dat verdikte JLS in de vroege zwangerschap een 
aanwijzing zijn voor het ontwikkelen van een verdikte NT. In een observationele studie werd 
de aanwezigheid en meetbaarheid van JLS getest om te beoordelen of het een geschikte 
vroege marker is. In deze context was de toevoeging van de JLS meting onafhankelijkheid 
van de gemeten NT en de associatie met chromosomale afwijkingen een voorwaarde. De 
afwezigheid van JLS zou mogelijk gebruikt kunnen worden om chromosomale afwijkingen uit 
te sluiten (negatief voorspellende waarde). De detecteerbaarheid van JLS is echter 
afhankelijk van de resolutie van de echomachine. Het echoscopisch in beeld brengen van 
JLS kleiner dan 2,0 mm is een tijdrovende bezigheid en vereist speciaal getrainde en 
bekwame echoscopisten. Er kon geen meerwaarde voor JLS in de eerste-trimesterscreening 
aangetoond worden en er bleek afhankelijkheid van JLS in combinatie met een verdikte NT.  
Hoofdstuk 6. De eerste-trimestercombinatietest is een veel gebruikte en erkende test voor 
screening op trisomie 21, 13 en 18. Als er een gecorrigeerd individuele kans van 1 op 200 of 
hoger wordt gevonden, is er sprake van een verhoogde kans en komt de zwangere in 
aanmerking voor invasieve diagnostiek (vlokkentest of vruchtwaterpunctie). Sommige 
zwangere vrouwen zien op tegen een dergelijk invasieve test omdat deze geassocieerd is 
met een kans op een miskraam (0,3-0,5%). In dit hoofdstuk is onderzoek gedaan naar de 
toegevoegde waarde van bepaling van zogenaamde specifieke echomarkers. Deze 
echomarkers zijn het neusbotje (nasal bone), de hoek van het aangezicht met de bovenkaak 
(fronto-maxillary facial angle), het stroomprofiel van de ductus venosus en de functie van de 
rechter hartklep (tricuspid regurgitatie). De beoordeling en resultaten van deze echomarkers 
werden gecombineerd met NT en biochemie. Hieruit werd opnieuw een individueel 
kansberekening gemaakt. Deze benadering werd de combinatietest-plus (CT-plus) 
genoemd. Het CT-plus onderzoek werd aangeboden aan vrouwen met een verhoogd 
individuele kans tussen 1 op 200 tot 1 op 50. Na het CT-plus onderzoek werd altijd de 
invasieve diagnostiek alsnog aangeboden.  
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De CT-plus test scoorde relatief goed op de correctie van de zogenaamde foutpositieve 
testuitslagen. CT-plus kan worden ingezet om het aantal foutpositieve uitslagen, ofwel het 
hoge aantal onterechte hoog-risico uitslagen omlaag te brengen en daarmee het aantal 
invasieve ingrepen met kans op miskraam t.g.v. die ingreep te verminderen. CT-plus 
onderzoek scoort echter onder de maat als het gaat om de detectie van 
chromosoomafwijkingen (lage sensitiviteit) heeft niet bijgedragen aan een betere identificatie 
van chromosomale afwijkingen. De toegevoegde waarde van het CT-plus onderzoek bij deze 
categorie vrouwen is om die reden beperkt 
Hoofdstuk 7. Chromosomale afwijkingen worden vaak geassocieerd met groeivertraging. 
Vooral trisomie 18 is bekend om de vroege uiting van een verstoring in groei. Dit verschil is 
minder zichtbaar bij trisomie 13 en monosomie X. Bij trisomie 21 verloopt de groei, uitgedrukt 
in de CRL meting, echter ongeveer gelijk aan die van normale foetus. De CRL metingen 
worden traditioneel uitgevoerd in 2 dimensionale (2D) echoscopie. Met de introductie van 3 
dimensionale (3D) echoscopie werd het mogelijk om embryonale en foetale volumes te 
meten. Met de komst van Virtual Reality kunnen 3D volumes in een holografische projectie 
(I-Space) worden omgezet en kunnen volumes nauwkeurig worden gerekend. Eerdere 
studies hebben aangetoond dat terwijl de CRL verdubbelde, het volume 5 tot 6 maal toenam. 
Met deze technieken en eerdere studies werden de volumes van chromosomaal afwijkende 
foetus vergeleken met die van normale foetus. Bij meting van de volumes bleken 
respectievelijk de verschillen van foetus met trisomie 21 met -28%, foetus met trisomie 18 
met -42,5%, foetus met trisomie 13 met -43,4% en monosomie X met -35,5% kleiner dan de 
volumes van normale foetus. Het abnormale volume van chromosomaal afwijkende foetus 
kan worden verklaard door langere duur van de celcyclus ten gevolge van zogenaamde 
‘checkpoint controlegenen’ met als resultaat een significant verlaagd aantal cellen in 
vergelijking met normale foetus. Het meten van het foetale volume kan een toegevoegde 
waarde hebben in de vroege screening en diagnose van chromosomaal afwijkende foetus. 
Hoofdstuk 8. De toegevoegde waarde van 3D echoscopie en de I-Space komen ook tot 
uiting in de bespreking van een goed gedocumenteerde registratie van een foetus met een 
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specifieke chromosomale afwijking die alleen in de placenta kon worden aangetoond 
(mozaïek trisomie 16) In het kader van onderzoek met 3D en I-Space werden wekelijkse 
metingen werden verricht in het eerste trimester van de zwangerschap (van week 5-6 tot en 
met week 13-14) en daarnaast werd de zichtbare anatomische ontwikkeling (vooral 
ontwikkeling van de ledematen) van de foetus vergeleken met de ontwikkelingsstadia van de 
foetus beschreven aan de hand van de Carnegie Stadia. In deze casus bleek een 
discrepantie tussen de zwangerschapsduur gebaseerd op een zekere laatste menstruatie 
met regulaire cyclus en de echoscopische termijnbepalingen op basis van de CRL. 
Daarnaast werd een verdikte nekplooi waargenomen. Aanvullende invasieve diagnostiek 
(vlokkentest en vruchtwaterpunctie) werd aansluitend verricht. Hieruit bleek dat er sprake 
was van een placentaire trisomie 16. De zwangerschap werd verder nauwkeurig gevolgd met 
2D en 3D echoscopie. Er werden geen structurele afwijkingen gezien. De groei bleef 
symmetrisch te klein voor de verwachte zwangerschapsduur. De 3D echoscopie en 
beoordeling in de I-Space hebben bijgedragen aan de vroege detectie van de groei- en 
ontwikkelingsvertraging bij een chromosomale afwijking. 
In de algemene discussie, het laatste deel en hoofdstuk 9 van dit proefschrift, worden de 
resultaten uit alle studies besproken en waar mogelijk gecombineerd. Het doel was het 
bediscussiëren van de methodologische aspecten van de eerste-trimestercombinatietest 
(CT) en de invloed van kleine veranderingen binnen de biochemische en echoscopische 
onderdelen van de test en de toepasbaarheid daarvan in de dagelijkse praktijk. Daarnaast 
zijn nieuwe echotechnieken belicht. Met de intrede van de non-invasieve prenatale test 
(NIPT) lijkt de rol van CT niet veranderd. Wanneer de uitslag van de CT een verhoogde kans 
voor trisomie 21, 13 en/of 18 aangeeft van 1 op 200 of hoger, kan van april 2014 in een 
testfase gekozen worden voor verdere diagnostiek met NIPT, naast de reeds bekende 
invasieve diagnostische technieken (vlokkentest en vruchtwaterpunctie) met kans op een 
miskraam. t.g.v. de punctie. 
Het echo-onderzoek tussen de 11de en 14de week van de zwangerschap is niet alleen voor 
het meten van de CRL en de NT. Het kan en wordt ook steeds vaker gebruikt als een vroege 
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structurele scan van de foetale structuren en vroege diagnostiek van ernstige foetale 
afwijkingen. Hierin kunnen, vooral bij hartafwijkingen, de eerder beschreven Doppler 
sonomarkers een grote rol in spelen. De mogelijkheden van NIPT moeten gezien worden als 
toegevoegde waarde in plaats van een vervanging van de combinatietest. 
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Word of thanks/Dankwoord 
 
Er zijn momenten geweest dat ik, tijdens het werken aan dit proefschrift, getwijfeld heb of ik 
ooit toe zou komen aan het schrijven van een dankwoord. Op privéterrein zijn er in de 
afgelopen jaren veel veranderingen, aanpassingen en tegenslagen geweest, waardoor het 
proefschrift soms naar de achtergrond verdween. Ook een verandering in wonen en werk 
heeft zo een rol gespeeld. Hoe buigzaam een mens moet en kan zijn, blijkt uit het feit dat het 
proefschrift er dan toch eindelijk ligt. Zoiets lukt je ook nooit alleen. Bij alles wat er gebeurt, 
spelen andere mensen altijd een rol, hoe klein soms ook. Hoe dan ook, moet er een woord 
van dank gericht worden aan bepaalde mensen. Ook al kan ik hier niet iedereen bij naam 
noemen, weet dan dat jouw aandeel ook onmisbaar was in het geheel. 
 
Prof.dr. E.A.P. Steegers, mijn promotor. Beste Eric, we zijn in hetzelfde jaar in het Erasmus 
MC begonnen. Met jouw komst heeft de subafdeling Verloskunde en Prenatale Diagnostiek, 
zoals dat toen nog heette, veel nieuwe impulsen gehad. Ik mocht als projectleider de intrede 
van de klinisch verloskundigen op de afdeling verloskunde begeleiden. Continuïteit in zorg 
op de afdeling en het bruggen slaan tussen de verschillende beroepsgroepen. Het begin van 
ketenzorg in Rotterdam, de start van de eerste-lijngeboortecentra en het ontwikkelen van 
een HBO-Master voor klinisch verloskundigen. Een ander belangrijk onderdeel was de 
introductie van preconceptiezorg. Jij bent degene die mij hiervoor enthousiast heeft gemaakt, 
misschien wel, belangrijkste deel in de verloskundige zorg. Of om jouw woorden te spreken: 
“Begin bij het begin”. Het heeft er zelfs toe geleid om onderzoek te gaan doen naar het 
toepassen in de eerste lijn en het schrijven van een eerste artikel. Deze introductie in het 
wetenschappelijk onderzoek en de overstap van Verloskunde naar de Prenatale 
Geneeskunde zijn de basis geworden voor dit proefschrift. Eric, bedankt voor de kansen, je 
vertrouwen, steun, geduld en de vrijheid die je mij gegeven hebt om dit tot een goed einde te 
brengen. 
 
168 
 
Mijn copromotor: Dr. H.I.J Wildschut, beste Hajo. Binnen de groep Prenatale Geneeskunde 
hadden we allebei de passie voor prenatale screening in het eerste trimester die in 2007 
landelijk werd ingevoerd. Vele uren hebben we gediscussieerd over opzet en uitvoering, 
problemen en oplossingen. Jouw manier van denken, taalgevoel, schrijven en 
wetenschappelijk onderzoek spraken mij altijd aan. Maar ook je kijk op het leven en je gevoel 
voor humor. Ik heb veel van je geleerd. Het was dus voor ons allebei vanzelfsprekend dat jij 
mijn copromotor zou worden. We hebben veel en intensief contact gehad. Het ging gelukkig 
niet altijd over prenatale screening of verloskunde. We delen nog een passie: Curaçao. Jij 
hebt daar met je lieve vrouw en je gezin jaren geleefd, gewerkt en jouw proefschrift ‘The 
Curaçao Perinatal Mortality Survey’ geschreven. Allebei zijn we ondertussen een andere 
kant op gegaan. Jij ging naar Hoorn en ik naar Curaçao. Daar is nu ook mijn proefschrift tot 
een goed einde gekomen. De contacten en discussies zijn gewoon doorgegaan, maar nu 
vaak via de mail en een enkele keer op Curaçao, onder het genot van een biertje. De band is 
gebleven en zal er altijd blijven. 
 
Een wetenschappelijk artikel schrijven doe je nooit alleen. Er zijn gelukkig altijd wel 
coauteurs geweest, die de publicatie naar een hoger niveau wisten te tillen.  
Helen Brandenburg, tijdens de vele vlokkenspreekuren die we samen hebben gedaan en de 
gesprekken die we hebben gehad, was jij het die mij leerde ook naar de kleine dingen te 
kijken en scherp op te letten op de kleinste veranderingen en tegenstellingen.  
Piet Struijk, jij bent in de begin periode mijn steun en toeverlaat geweest wat betreft het 
interpreteren van onderzoekdata, verwerking en statistiek. Maar ook met je scherpe vragen 
en opmerkingen wist je het onderste bij mij naar boven te halen. Gelukkig was er ook altijd 
ruimte voor koetjes en kalfjes. Altijd met een grote dosis humor en zelfspot. 
Jacqueline Laudy, binnen het kader van het biochemische aspect van de eerste-
trimesterscreening heb je mij met jouw kennis en de mogelijkheden van het laboratorium van 
Star-MDC, alle mogelijke ondersteuning gegeven. Uren heb ik bij jou in jullie database 
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mogen spitten, dingen uit te zoeken en andere berekeningen te maken. Samen met Yolanda 
de Rijke heb je zorg gedragen voor een sluitend biochemisch verhaal. 
 
Christine, Melek en Leonie. Met jullie heb ik achtereenvolgend een werkkamer mogen delen. 
In die periode heb ik veel van jullie geleerd over onderzoek naar de vroege zwangerschap 
met 3D en I-Space. Intrigerende materie, die heeft geleid tot een combinatie van jullie 
onderzoekslijn en mijn proefschrift. Daarnaast hebben we veel gesprekken gevoerd. Niet 
alleen over werk, maar juist ook over de gewone dingen in het leven. Twee 
zwangerschappen, één huwelijk en jullie promoties heb ik mogen meemaken. Bedankt voor 
het aangename gezelschap en de leuke en leerzame tijd op kamer He-115. 
Natuurlijk zijn er ook nog door de jaren heen de oude en nieuwe collega’s van de afdeling 
Prenatale Geneeskunde; In het bijzonder Els, Karin, en Ronald, die mij hebben geholpen om 
de verschillende databases op te bouwen. Verder natuurlijk ook speciale dank aan de 
andere collega’s: Hajo, Helen, Miriam, Annemarie, Aisha, Ingrid, Maarten, Titia, Margreet, 
Ernst, Irene, Hein, Averil, Nina, Charlotte, Jerome, Krista, Alex, Niek en Attie.  
Een afdeling is niets zonder ondersteuning van een secretariaat. Anneke, Leonie, Petra, Ria 
en Tilly, bedankt voor jullie hulp, begrip en humor. Er was altijd tijd voor een praatje en een 
grap. Jolanda Claessens, jouw hulp was echt onmisbaar bij afronding van dit proefschrift. 
 
Op Curaçao bijzondere dank aan: René, Berdi, Herman, Marco, Sanne en Denise. 
Everybody needs a buddy! Thanks for being there, diving with me and hunting Lionfish.. 
 
Vanuit mijn vier geweldige kinderen heb ik altijd onvoorwaardelijk steun mogen ontvangen.  
Philippe, Camille, Jeannot en Pascale, bedankt voor jullie liefde en vertrouwen. 
Ieder op zijn/haar eigen en unieke manier maakt mij elke dag trots dat ik jullie vader mag 
zijn.
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